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Myasthenia gravis (MG) is a B cell mediated autoimmune disease that is characterized 
by muscle weakness and fatigue and associated with autoantibodies directed against 
muscle acetylcholine receptor (AChR) at the neuromuscular junction. Detection of these 
antibodies has an important role in the diagnosis, treatment and management of the 
disease. The antibodies are partly produced by the autoreactive B cells in germinal 
centres formed in the medulla of the myasthenia thymus, where there are also thymic 
muscle-like cells that express fetal AChRs. The antibodies circulate to the 
neuromuscular junction leading to complement mediated lysis of the membrane and 
internalization of AChRs. The patients are successfully treated by corticosteroids, 
plasmapheresis and immunotherapies that reduce the levels of circulating antibodies. 
The AChR antibodies are disease specific and thought to be pathogenic but the 
mechanisms involved in the failure of tolerance is not well understood. In addition, the 
treatments are non-specific. Better treatments, targeted at acetylcholine receptor specific 
B cells, or the plasma cells that make the antibodies, would be preferred. 
The aim of the thesis was to try to characterize AChR autoantibodies from B cells in the 
myasthenia gravis thymus gland. The first steps were to test sera, from patients whose 
thymic lymphocyte populations had been archived by Prof N Willcox, in order to 
identify cultures that contained cells synthesizing AChR antibodies. 
Radioimmunoprecipitation and cell-based assays using human embryonic kidney 
(HEK293T) cells transfected with adult or fetal AChR with additional rapsyn-EGFP 
(enhanced green fluorescent protein), were used to measure the antibodies. Thymic 
cultures were tested from selected patients to identify AChR synthesis. The next step 
was to identify the AChR-antibody specific B cells; a novel approach was to use 
extracellular membrane vesicles prepared from the transfected cells expressing the 
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AChRs clustered with the intracellular protein rapsyn. Finally, the peripheral blood 
mononuclear cells (PBMCs) and thymic lymphocytes were characterized by 
fluorescence activation cell sorting (FACS), and the binding of AChR vesicles to CD19 
positive B cells examined. 
The radioimmunoprecipitation assay was able to detect serum AChR antibodies in MG 
patients’ sera and to a lesser extent in thymic cell cultures. The cell-based assay also 
detected clustered AChR antibodies in sera of the majority but not all MG patients. 
Because the thymus gland contains fetal AChR rather than the adult form, fetal AChR 
antibodies were tested and found to be more highly represented in the patients than the 
antibodies to the adult form. Extracellular membrane vesicles expressed AChRs as 
shown by immunostaining and western blotting. FACS analysis of the AChR/rapsyn-
EGFP membrane vesicle preparation showed that they could be detected by this method. 
To develop the methods for detecting the AChR antibody producing specific B cells, 
FACS analysis of lymphocyte populations was established in Raji cells and peripheral 
blood lymphocytes, and finally in the thymic cultures of two myasthenia patients. 
Analysis of CD19+ B lymphocytes from one selected thymic culture was incubated with 
AChR expressing vesicles which demonstrated binding of the vesicles to a population of 
B cells. 
The work done in this thesis partially achieved the aims of developing the methods for 
identifying AChR-specific B cells by use of AChR-expressing membrane vesicles and 
has provided the basis for further work. For this confirmation of the results, fresh thymic 
preparations from patients would clearly be desirable rather than the archived 
preparations available at the time of this work. 
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      1.1 Autoimmunity 
 
Autoimmunity is a misguided immune response to the body's own proteins with or 
without damage to the organ. Autoimmune diseases can have a variety of different 
effects on the individual. Classically, they usually have one of three characteristic 
pathological effects which characterize them as autoimmune diseases:  damage to   or 
destruction of tissues altered organ growth or altered organ function (Ada&Rose,1988).  
 
The human immune system produces both T-cells and B cells that are capable of being 
reactive with self-antigens, but these self-reactive cells are either usually deleted in th 
thymus before becoming active within the immune system or suppressed within the 
immune system by regulatory cells. In case of failure of any of these mechanisms, self- 
reactive cells can become functional within the immune system. The mechanisms of 
preventing self-reactive T-cells from being created takes place through negative 
selection process in the thymus (Ada & Rose, 1988 and Yin et al., 2013). 
Neurological autoimmunity can target virtually any cell or protein within the central or 
peripheral nervous system, often in a highly specific manner. As the different CNS cells 
or structures can be targeted, the syndromes can be diverse. The main known targets are 
the myelin sheath in multiple sclerosis, the astrocyte in neuromyelitis optica (NMO), the 
peripheral nerve myelin in immune neuropathies, and the neuromuscular junction in 
myasthenia gravis (MG). The diseases can result in clinical features such as blindness 
from optic neuritis, paralysis from spinal cord myelitis, and epilepsy or memory changes 
from brain inflammation. There are also a new group of conditions caused by antibodies 
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to receptors on neuronal cells. Understanding these disorders ultimately requires an 
analysis of how the target antigen molecules generate the autoimmune reaction and how 
the immune system produces the immune–mediated injury of the nervous system. 
Cytokines, autoantibodies, and other immune factors like complement factors, human 
leukocyte antigens (HLA) all contribute to the diseases. 
The focus of this Thesis is on myasthenia gravis (MG) but a few comments will first be 
made about other well-characterized common autoimmune diseases. 
1.1.i Systemic lupus erythematosus (lupus/ SLE) is an autoimmune inflammatory 
disease characterized by interferon and complement activation, autoantibodies and tissue 
destruction involving multiple organ systems (Rahman& Isenberg, 2008). In addition, 
activation of type I interferons was also prevalent in SLE and associated with distinct 
autoantibody profiles (Weckerleet.al., 2011). Common clinical symptoms in SLE 
include rash, nephritis, central nervous system disease, thrombocytopenia and 
musculoskeletal manifestations. SLE often occurs in women between 20–40 years of 
age and has strong genetic and environmental components. (Rahman P et.al., 1999). 
 
 
1.1.ii Multiple Sclerosis (MS): Although this is predominantly an inflammatory disease 
associated with T lymphocyte infiltrates into the brain, B cells and T cells are both major 
players in the pathogenesis of multiple sclerosis (MS) and cooperate at various check 
points. B cells isolated from CNS lesions as well as from the cerebrospinal fluid (CSF) 
show signs of clonal expansion and hypermutation, suggesting their local activation 
(Weber et.al., 2011). Plasmablasts and plasma cells maturing from B cells contribute to 
the development of oligoclonal antibodies produced within the CSF, which remain a 
diagnostic hallmark finding in MS. B cells, besides serving as the precursors for 
antibody-secreting plasma cells, are efficient antigen presenting cells for 
3  
processing of intact myelin antigen and subsequent activation and pro-inflammatory 
differentiation of T cells; these mechanisms are supported by the immediate clinical 
benefit of therapeutic B cell depletion in MS. Within the CNS, antibody deposition is 
associated with complement activation and demyelination. Some studies have implied a 
pathogenic role of antibodies directed against components of the myelin sheath. The 
notion of a pathogenic role for antibodies in MS was supported by the plasma exchange 
in patients with histologic signs of antibody deposition within the CNS but only in a 
minority of patients (Weber et.al.,2011). 
 
 
1.1.iii Rheumatoid arthritis (RA): RA is a chronic autoimmune disease that mainly 
affects the joints. (Scott et.al., 2010). The immune system produces antibodies that 
attacks to the linings of joints in our body. A large proportion of RA patients are 
characterized by the presence of antibodies directed against post-translationally 
modified proteins, especially proteins that are citrullinated (Klareskoget.al., 2008). The 
antibodies against such proteins are called anti-citrullinated protein antibodies (ACPA) 
and recognize proteins only when they contain the modified, ‘non-encoded’, amino acid 
citrulline. Untreated RA gradually causes permanent damage to the joints (Burskaet.al., 
2014). 
 
1.1.iv Chronic inflammatory demyelinating polyneuropathy (CIDP): This disease is 
similar to Guillian-Barre syndrome; the immune system also attacks the peripheral 
nerves in CIDP, but symptoms last much longer. About 30% of patients can become 
confined to a wheelchair if not diagnosed and treated early. Treatment for CIDP and 
GBS are essentially the same. Anti-thymocyte globulin, from animals that were 
immunized against human thymocytes, was used formerly. Intravenous immunoglobulin 
therapies are now the main treatments for CIDP. Immunosuppressive drugs such as 
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rituximab which target B cells are a more recent approach to treat CIDP from 2004 
(Odaka et.al., 2005). 
 
1.1.v Diabetes mellitus type 1, Diabetes mellitus (DM) is a disease of glucose 
metabolism characterized by chronic hyperglycemia resulting from defects in insulin 
secretion or insulin action (Skyler et.al., 2017). Type 1 (T1) DM results from an 
absolute deficiency in insulin caused by the loss of insulin-secreting islet cells in the 
pancreas, while type 2 (T2) DM is characterized by insulin resistance and relative 
insulin deficiency, either or both of which may be present at the time diabetes is 
diagnosed. According to the updated data from the international diabetes federation 
(IDF), the estimated global prevalence of DM reached 8.8% in 2015 and 12% of global 
health expenditure was due to DM in that same year (Yates et.al.,2016). Attempts to 
understand the pathogenesis of DM are still ongoing. T1DM was traditionally 
considered an autoimmune disease; early research demonstrated that T cells were 
involved in various pathogenic steps in T1DM, including the initiation of insulitis and  
the injury to β cells (Wong et.al., 1997). Moreover, recent research has also discovered 
the role of T cells in the development of insulin resistance (Jagannathan-Bogdan et.al., 
2011) and various complications in T2DM. Thus, T cells may be a key component in the 
pathogenesis of DM as well as a potential diagnostic and therapeutic target. 
 
1.2 Immunoglobulin molecules 
 
 
Immunoglobulins, also known as antibodies, are glycoprotein molecules produced by 
plasma cells (white blood cells). They act as a critical part of the immune response by 
specifically recognizing and binding to particular antigens, principally infectious 
microbes, but they can also react to self to cause autoimmunity. The antibody immune 
response is highly complex and exceedingly specific. The various immunoglobulin 
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classes and subclasses (isotypes) differ in their biological features, structure, target 
specificity and distribution. Antibody or Ig molecules are glycoproteins composed of 
one or more units, each containing four polypeptide chains. Heavy and light chains are 
held together by a combination of non-covalent interactions and covalent interchain 
disulfide bonds. 
 
Immunoglobulins occur in two main forms, soluble antibodies and membrane-bound 
immunoglobulins; the latter are associated noncovalently with two accessory peptides, 
forming the B-cell antigen receptor complex. Alternative splicing regulates the 
production of secreted antibodies and surface bound B-cell receptors in B cells. The 
receptor is a prototype of the antibody that the B cell will make. The B cell receptor 
(BCR) binds specific antigens. It is a heterodimer of Ig alpha and Ig beta chains that 
enable the cell to transduce the signal and respond to the presence of the antigen on the 
cell surface. The signal generated causes the growth and proliferation of the B cell 
which transitions to a plasma cell that secretes the antibodies. 
 
1.3 Immunoglobulins and their functions 
 
 
Antibodies are classified into classes and subclasses. The five primary classes of 
immunoglobulins are IgG, IgM, IgA, IgD and IgE. These are distinguished by the type 
of heavy chain found in the molecule. IgG molecules have heavy chains known as 
gamma-chains. The light chains are known as kappa and lambda. 
IgG is the major immunoglobulin in blood, lymph fluid, cerebrospinal fluid and 
peritoneal fluid and a key player in the humoral immune response. Serum IgG in healthy 
humans represents approximately 15% of total protein beside albumins, enzymes, other 
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globulins and many more. IgG is the only class of Ig that can cross the placenta in 
humans. 
 
There are four IgG subclasses described in human. The subclasses differ in the number 
of disulfide bonds and the length and flexibility of the hinge region. Except for their 
variable regions, all immunoglobulins within one class share about 90% homology, but 
only 60% among all the classes. 
 
Of the five antibody classes, only significant amounts of IgG are transferred across the 
placenta. Whole IgG molecules or Fc fragments of IgG pass into the fetal circulation 
more readily than F(ab′)2 fragments (Brambell et.al., 1960). The Fc portion of IgG, but 
not Fab fragments, can cross the placenta of a mother and enter the fetal circulation, 
providing the fetus with postpartum protection (Palmeira et.al., 2012). It was 
hypothesized that IgG Fc receptors (FcγRs) on placental cells may be involved in IgG 
transfer across placenta. Later, it was established that this specific transport of IgG is 
carried out by the neonatal Fc receptor (FcRn) (Simister&Mostov.,1989). IgG molecules 
can react with Fcγ receptors that are present on the surface of macrophages, neutrophils 
and natural killer cells, and can activate the complement system. IgG is produced in a 
delayed response to an infection and can be retained in the body for a long time. The 
longevity in serum makes IgG most useful for passive immunization by transfer of this 
antibody. Detection of a specific IgG usually indicates a prior infection or vaccination, 
or sometimes an autoimmune disease. This is a very important aspect of early onset 
myasthenia (EOMG) gravis which is discussed further below. 
 
In cases with prolonged or severe infections, determination of IgG levels can provide 
additional insight into the manifestation of disease. It is important to interpret IgG 
subclass concentrations in correlation to the donor's age since the immune system 
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matures during childhood. Due to its relative abundance and excellent specificity toward 
antigens, IgG is the principle antibody used in immunological research and clinical 
diagnostics. 
 
IgG1 comprises 60 to 65% of the total main subclass IgG and is predominantly 
responsible for the thymus-mediated immune response against proteins and polypeptide 
antigens. IgG1 binds to the Fc-receptor of phagocytic cells and can activate the 
complement cascade via binding to C1 complex. IgG1 immune response can already be 
measured in newborns and reaches its typical concentration in infancy (Vidarsson et.al., 
2014). IgG2, the second largest of IgG isotypes, comprises 20 to 25% of the main 
subclass and is the prevalent immune response against carbohydrate/polysaccharide 
antigens. IgG2 is most commonly associated with airway/respiratory infections in 
infants (Vidarssonet.al., 2014). IgG3 comprises around 5 to 10% of total IgG and plays a 
major role in the immune responses against protein or polypeptide antigens. The affinity 
of IgG3 can be higher than that of IgG1 (Plomp R et.al., 2015). IgG4 is usually less 
than 4% of total IgG, IgG4 does not bind to polysaccharides. Recent studies have shown 
that elevated serum levels of IgG4 are found in patients suffering from sclerosis, 
pancreatitis and interstitial pneumonia caused by infiltrating IgG4 positive plasma cells. 
The precise role of IgG4 was unknown (Vidarssonet.al., 2014) but recent studies reveal 
that IgG4 plays a role in autoimmune neuropathies and myasthenia gravis associated 
with MuSK antibodies. IgG4 are not complement activating, unlike the IgG1 and IgG3 
AChR antibodies (McConville et.al., 2004), and the antibodies act by direct inhibition of 
function of the antigen molecules (Huijberset.al., 2014; Huijberset.al., 2015) 
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IgM is also expressed on the plasma membrane of B lymphocytes as a monomer. IgM is 
the first antibody built during an immune response. Pentameric structure of IgM is the 
largest structure among all the immunoglobulins. IgM are produced by B cells usually in 
the spleen. Recent studies have shown the role of IgM in CSF of multiple sclerosis (MS) 
patients (Beltran et.al., 2014). 
 
 
IgE is primarily involved in defence against parasitic invasion but is also responsible 
 
for   allergic   reactions. IgE   protects   against   various   parasitic infections  
(Capron et.al.,1977) but it is known to mediate type I hypersensitivity since 
it binds the high affinity receptor for IgE on mast cells and basophils. (Blank & Rivera, 2004). 
 
IgD is the major antigen receptor isotype on the surface of most peripheral B cells, 
 
where it is coexpressed with IgM (Van Boxelet.al., 1972).   
 
 
The role of secretory IgA is to prevent passage of foreign substances into the circulatory 
system. IgA has been relatively associated with various autoimmune diseases such as 
MG, SLE, RA and type 1 diabetes but, although its prevalence differs between ethnic 
groups, there are no known disease associations with IgA antibodies (Wang et.al., 
2011). 
 
1.4 B cells in autoimmunity 
 
B cell development and function is tightly regulated, including the induction of B cell 
memory and antibody secreting plasmablasts and plasma cells, one of the major roles of 
B cell lineage. B cells subsets and markers were based on the developmental stages of a 
B cell and its exposure to antigens. As B cells mature and differentiate, they give rise to 
functionally distinct subsets. Differential expression of cell surface and intracellular 
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markers, as well as their distinct immunoglobulin and cytokine secretion profiles, 
provide understanding of diverse nature and function of the different B cell subsets. B 
cells originate from hematopoietic stem cells (HSCs) located in the bone marrow, 
migrate to secondary lymphoid tissues for their development into follicular B cells. 
When the B cell receptor complex of a mature B cell, consisting of membrane bound Ig, 
interacts with an antigen, the cell becomes activated and differentiates into an ab 
secreting plasma cell. Autoreactive B cells can potentially be generated at several stages 
during B cell development and there is some evidence that a promoter FcYRIIB 
mediates its function during the antigen dependent stages of maturation (Dörner, 
Jacobi& Lipsky., 2009). 
 
B cells evolve under tightly regulated mechanisms along with other immunocompetent 
cells and historically, B cells were not considered to play a major regulatory function in 
the development of autoimmunity or autoimmune disease. However, the identification 
of autoantibodies and their pathogenicity is now widely accepted. 
1.5 Role of the thymus 
 
The normal thymus is an epithelial organ that can be divided into cortex, medulla and 
corticomedullary zone. The cortex contains immature lymphocytes alongside epithelial 
cells and macrophages. The medulla is less cellular containing more mature T 
lymphocytes, epithelial cells, dendritic cells and rare myoid cells. There are some B cells 
but germinal centres are not frequent. It plays a critical role in self-tolerance with a 
balance between the generation of T lymphocytes and deletion of autoreactive T cells. 
Some MHC molecules have strong associations with autoimmune disease. These MHC 
molecules are polymorphic, which influences the amino acids involved in binding 
peptide. One possible explanation for the disease association is that self-peptides do not 
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bind as well to these MHC molecules, which then compromise the efficiency of negative 
selection of self-reactive T cells in the thymus. 
 
1.6 Immunological tolerance 
 
T cells which react to self-antigens are usually tolerant to normal, physiological levels of 
self-antigen. However, in some people, self-destructive autoimmune disease develops 
because of the breakdown in tolerance mechanisms. This appears to be due to multiple 
factors, with contributions from gene defects, which confer autoimmune susceptibility, 
and environmental factors. Infectious agents or tissue damage from some other cause 
may activate the immune system, alter expression of self-antigen, or lead to expression 
of self-antigens which the immune system normally does not see. 
Normally immune responses against our own tissue are not made, a concept known as 
self-tolerance. Determining how the immune system distinguishes between self and 
foreign antigens to make the decision between tolerance and immunity has been a 
subject of detailed investigation during the past 50 years. A crucial observation, that 
suggested that tolerance to self-antigens occurred because the immune system was 
exposed to these antigens during early development, was made by R.D. Owen in 1945 
and the theory modified by J. Lederberg, who suggested correctly that it was the stage in 
the development or ontogeny of the lymphocyte that was critical, rather than the stage in 
development of the animal (see Basten, 1989). Central tolerance refers to mechanisms of 
tolerance acting by clonal deletion during lymphocyte development in the thymus or 
bone marrow whereas peripheral tolerance refers to mechanisms acting on mature 
lymphocytes after they have left the primary lymphoid organs. Peripheral tolerance acts 
by deletion and inactivation (anergy). Not all genes are expressed in the thymus so 
developing T cells cannot be exposed to all self-antigens. 
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B cell tolerance is most profound to soluble antigens expressed in the serum or on the 
surface of cells. Normally, B cells specific for these self-antigens are deleted in the bone 
marrow or shortly afterwards. By contrast, there are high affinity autoantibodies to 
antigen normally isolated within cells, suggesting that B cells specific for intracellular 
self-proteins may escape clonal deletion. However, some antibodies recognize 
extracellular cell-surface self-antigens. For instance, B cells secreting the IgM 
haemolytic antibody are also present in normal individuals, but the level of expression is 
so low that there is no direct cell destruction. When the level of IgM antibody is 
increased by infection, autoimmune haemolysis occurs. 
 
Mechanisms of peripheral B cell self-tolerance are particularly necessary because after 
stimulation with antigen B cells expand and undergo somatic mutation, generating a 
population of B cells with new antigen specificities. Some of these cells may be specific 
for self-antigens. 
 
Although the principal mechanisms of tolerance to self-antigens are clonal deletion and 
anergy, there is also a back-up mechanism called suppression. This is a form of 
dominant tolerance because suppressor cells specific for a given antigen are able to 
inactivate other lymphocytes specific for the same antigen. 
 
There is now a large amount of evidence to support the Clonal Selection Theory for both 
T and B cells, but deletion of lymphocytes specific for self-antigens is not the only 
mechanism of self-tolerance. Both T and B cells specific for self-antigens can be 
identified in healthy people, so there must be mechanisms that prevent such cells from 
becoming activated and damaging self-tissue, thereby causing autoimmune diseases. 
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The existence of autoimmune diseases reveal that lymphocytes reactive to certain self- 
antigens do exist in the body as mentioned above. In some circumstances, the self- 
antigen may have been previously hidden from the immune system so that lymphocytes 
have not had an opportunity to become tolerant. Therefore, immunocompetent B cells 
which recognize the self-antigen and which require T cell help in order to be activated 
are able to respond. Finally, these potentially autoreactive cells may be activated by a 
potent inflammatory stimulus. 
Pathogenic autoantibodies are more commonly associated with non-organ-specific 
systemic autoimmune diseases. Transfer of autoantibodies to experimental animals may 
confirm their pathogenic role, although this approach is limited by inter species 
differences in target antigens. Work on myasthenia gravis in particular, however, has 
demonstrated the validity of this approach. 
 
There are five principle mechanisms by which autoantibodies can produce autoimmune 
disease: 
 
1. Complement dependent lysis of the target cell. 
 
 
2. Opsonisation. This is the mechanism of most forms of haemolytic anaemia as the 
density of Ig is insufficient to allow cross-linking and activation of C1q. 
 
3. Formation of immune complexes in the circulation. 
 
 
4. Blockade of receptors for physiological ligands or loss of surface expression by 
internalization. e.g. Myasthenia gravis (acetylcholine receptor antibodies), pernicious 
anaemia (intrinsic factor antibodies). 
 
5. Stimulation of cell surface receptors. e.g. Graves' disease. 
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1.7 Antibody mediated autoimmune neurological diseases 
 
 
1.7.1 Neuromyelitis optica (NMO) 
 
NMO is an idiopathic, demyelinating disease of the central nervous system that affects 
the optic nerve and spinal cord and causes optic neuritis (ON) and longitudinally 
extensive transverse myelitis. NMO has a worldwide distribution, poor prognosis, and 
has long been thought of as a variant of multiple sclerosis; however, clinical, laboratory, 
immunological, and pathological characteristics that distinguish it from multiple 
sclerosis are now recognized. The presence of a highly specific serum autoantibody 
marker (NMO-IgG) differentiates neuromyelitis optica from multiple sclerosis and has 
helped to define a neuromyelitis optica spectrum of disorders. NMO-IgG reacts with the 
water channel aquaporin 4. (Lennon et.al 2004; Bradl et.al., 2009). Autoantibodies to 
aquaporin 4 derived from peripheral B cells cause the activation of complement, 
inflammatory demyelination, and necrosis that is seen in neuromyelitis optica. The 
knowledge gained from further assessment of the exact role of NMO-IgG in the 
pathogenesis of neuromyelitis optica will provide a foundation for rational therapeutic 
trials for this rapidly disabling disease (Lennon et.al., 2005). 
 
1.7.2. Myasthenia gravis 
 
 
MG is an autoimmune syndrome caused by the failure of neuromuscular transmission, 
which results from the binding of autoantibodies to proteins involved in signalling at the 
neuromuscular Junction. The antibodies to the acetylcholine receptors (AChR) cause 
complement mediated destruction of the post-synaptic folds of the neuromuscular 
junction (NMJ) and internalization of the AChRs. This results in reduced muscle-nerve 
synaptic transmission and fatigable muscle weakness. It affects the voluntary muscles 
14  
including muscles of the neck, eyelids, limb and diaphragm. Fatigable weakness, 
involving these susceptible muscle groups, is the most characteristic feature of MG; 
fatigue becomes more evident on exertion and improves with rest. The course of MG is 
variable. Many patients experience intermittent worsening of symptoms triggered by 
infections, emotional stress, surgeries, or medications, particularly during the first year 
of the disease (see Vincent, 2002; Vincent et.al., 2008). 
 
The prevalence of MG is 1–2/10,000 persons and is increasing probably due to 
increased longevity and improved diagnostic and treatment strategies that prolong life. 
The incidence varies between 1.7 and 21 per million inhabitants. The incidence had 
increased in older individuals (Carret.al., 2010). 
In autoimmune myasthenia gravis, the majority of cases are caused by antibodies 
targeting the acetylcholine receptor as measured by radioimmunoprecipitation assays. 
The role of the antibodies that cause myasthenia gravis was clearly established in the 
1970s. Immunisation against purified AChR produced evidence of myasthenic  
weakness in rabbits and mice (Patrick & Lindstrom, 1973), and injection of monoclonal 
antibodies to AChR produced similar effects in laboratory animals (Lennon & Lambert, 
1980).    In addition, injection of patient IgG antibodies into mice also produced signs of 
MG (Toykaet.al., 1977). Finally, plasma exchange, that removes circulating antibodies, 
lead to a substantial but transient improvement in muscle function lasting up to 2 months 
(Newson-Davis et.al., 1978).  
 
Approximately 15% of patients have a previously unexplained form of the disease. One 
cause was found to be antibodies to the protein MuSK in some of these individuals 
(Hoch et.al., 2001). Later more specific tests were developed named 'cell-based' 
antibody tests, which have helped to improve the sensitivity of both AChR and MuSK 
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antibody tests, and to provide tests for more antigens, leading to improved diagnosis of 
MG and related disorders. These will be discussed below. 
1.7.3 Diagnostic and clinical classification of MG 
 
Autoantibodies against AChR are typically present in 85% sera of MG patient 
(Lindstrom et.al., 1976) and antibodies to MuSK in only 40-70% of AChR-antibody 
negative patients (McConville et.al., 2004). There is convincing evidence that MuSK 
antibodies are pathogenic. They bind to the extracellular domain of MuSK and inhibit 
agrin-induced AChR clustering in cultured muscle myotubes (Hoch et.al., 2001). There 
are still, however, a number of ‘seronegative’ MG (SNMG) patients. About 60% have 
low-affinity antibodies against AChR undetectable by the radio-immunoprecipitation 
assays but which can be demonstrated on cell based assays where the AChR is clustered 
(Leiteet.al, 2008). 
1.8.1 The neuromuscular junction in MG 
 
The NMJ has three basic components, the presynaptic motor nerve terminal where 
acetylcholine is synthesised, stored, and released; the synaptic space where 
acetylcholine esterase is localized; and the postsynaptic muscle membrane where 
AChRs are densely packed (see Fig 1.1). Neuromuscular transmission begins with the 
entry of a nerve action potential into the nerve terminal. Exocytosis of synaptic vesicles 
containing acetylcholine require calcium, which enters the depolarised nerve terminal 
via voltage-gated Ca²+ channels. Acetylcholine diffuses across the synaptic cleft and 
interacts with the AChRs on the postsynaptic muscle membrane, leading to opening of 
the AChR ion channel and depolarisation. The action of acetylcholine on the AChRs is 
terminated by acetylcholinesterase. In MG, loss of functional AChRs results in the 
decrease of the threshold required for generation of the muscle nerve fibre action 
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Potential which, during repetitive nerve depolarisations, results in neuromuscular 
transmission failure. The NMJ with different antigenic targets are described 
diagrammatically in Fig 1.2 (see also Vincent, 2002). 
1.8.2 Structural characterization of AChRs 
 
AChR remains the major antigenic target in MG followed by MuSK, LRP4 and agrin. 
AChR is a pentameric membrane protein. Two isoforms of AChR, fetal and adult differ 
in the composition of five subunits: each contains two α1, one δ and one β1 subunits but 
the fetal receptor contains a γ that is replaced by a ε subunit in adult receptor. The 
subunits are organized around a central cation channel (Fig 1.3). The two binding sites 
between α and ε or γ and α and δ need to be occupied by the ACh for full activation to 
occur (Vincent, 2002). 
1.8.3 Autoantibodies in MG 
 
The antibodies in most MG cases are against the α1 subunit of the AChR 
 
(Kalamida et.al., 2007), and bind to the main immunogenic region (MIR) that is located 
on the extracellular domain of the two α subunits (Lindstrom et.al., 2000) (Fig 1.3). The 
binding sites for the MG antibodies were described by competition with monoclonal 
antibodies raised against the human AChR (see Jacobson et.al., 1999; Fig 1.4). The MG 
antibodies are mainly the complement fixing IgG1 or IgG3, which recognize the native 
conformation of the AChR. The conventional assay to detect AChR antibodies in the 
sera is a radioimmunoprecipitation assay which is based on the binding of 125I-α- 
Bungarotoxin (BuTx) to an equal mixture of fetal and adult AChR extracted from 
human muscle cell lines. The non-radioactive cell-based assay (CBA) uses human 
embryonic kidney cells (HEK cells) co-transfected with the AChR subunits and rapsyn 









Figure 1.1. Structure of NMJ, the ion channels involved in neuromuscular 
transmission. Acetylcholine containing vesicles (pink) are released from the 
motor nerve terminals. Acetylcholine receptors present on the postsynaptic side of 
muscle membrane interact with acetylcholine leading to depolarisation of muscle 
membrane. MuSK present at the AChR, maintains AChR on the post synaptic 










Figure 1.2. Signaling pathways at the neuromuscular junction. AChR - 
acetylcholine receptor; rapsyn – the AChR clustering molecule; AChE - 
acetylcholine esterase; LRP4 - Low density lipoprotein 4; Dok7 - 
downstream of tyrosine kinase 7. (Taken from Barber C., 2017) Diagnosis 






Figure 1.3. Structure of the AChR. Each subunit of AChR consists of a 
large extracellular domain and four transmembrane domains (above) 
that occur in an adult and foetal isoform. Most of the antibodies in MG 
bind to a main immunogenic region on the two α AChR subunits. In 
addition, some MG patients’ antibodies bind to fetal-AChR and can 







Figure 1.4. A diagrammatic representation of the five binding sites 
defined by monoclonal antibodies on the extracellular surface. The 
MIR and α-BuTx binding sites are located on the extracellular 
surface. None of the mAbs inhibit α-BuTx binding (taken from 
Jacobson et.al., 1999). 
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1.8.4 Different subgroups of MG 
 
Early-onset myasthenia gravis is defined as presenting before age 40 years and is more 
common in women. The majority are positive for AChR antibodies, and the thymus 
gland is enlarged and contains germinal centres. These patients also have antibodies to 
other muscle antigens, and some have other organ-specific autoantibodies (Oosterhuis, 
1989). About 60% of early-onset patients are HLA-B8 and DR3 positive 
(Compstonet.al., 1980; Garlepp et.al., 1982). 
 
Late-onset myasthenia gravis is defined as its first presentation in people older than 40 
years. The thymus gland is not enlarged, but there is an HLA association with B7 and 
DR2 (Compston et.al., 1980). Thymoma-associated myasthenia gravis can present at 
any age but the peak onset is during the fourth to sixth decades. There are no clear HLA 
associations. The patients usually have antibodies to other muscle antigens such as titin 
and ryanodine receptor (Aarli., 1999). 
 
Ocular weakness, presenting as fluctuating ptosis and/or diplopia, is the most common 
initial presentation of MG, occurring in approximately 85% of patients but around 80% 
will then develop generalized symptoms. Ocular myasthenia gravis is restricted to the 
eye muscles. The titres of antibodies to AChR are lowest in this subgroup, and 
undetectable in 40–60% of patients. However, electromyography and in-vitro studies on 
muscle biopsy samples indicate that the disease is probably present sub-clinically in 
other muscles (Sommer et.al., 1993). 
 
About 10–15% of patients have thymoma, while 30% of thymomas are associated with 
MG. Thymoma is equally common in men and women and is almost always positive for 
AChR antibodies. Thymoma is often associated with antibodies to titin or especially 
ryanodine receptor, both intracellular muscle proteins, and these patients may have more 
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severe disease course often characterized by progressive oropharyngeal weakness. 
Although the tumour must be removed, the symptoms usually persist after thymectomy 
unless immunotherapy treatments are given (Skeie, Romi., 2008).  
 
Neonatal MG occurs to about 10% of the babies born to the women having MG 
regardless of its presentation at the time of pregnancy. It is caused by placental transfer 
of maternal IgG AChR antibodies. The mothers tend to have raised titres of antibodies 
specific for the fetal isoform of the AChR (Riemersmae et.al., 1996) and the AChR 
antibodies are transferred to the fetus via the FcRn (as mentioned above). 
1.8.5. Muscle-specific kinase MG 
 
MUSK is a transmembrane protein involved in a signaling pathway that maintains the 
normal functional integrity of the NMJ (see Fig 1.2; Valenzuela et.al., 1995). MUSK 
antibodies are mainly IgG4 and are not complement activating, unlike the IgG1 and 
IgG3 AChR antibodies (Koneczny et.al., 2013). MUSK antibodies adversely affect the 
maintenance of AChR clustering at the muscle endplate, leading to reduced numbers of 
functional AChR (Shiraishi et.al., 2005). There is a radioimmunoprecipitation assay for 
MuSK and a highly sensitive and specific cell-based assay using MuSK-transfected 
HEK cells. Some of the sera of MuSK-MG reacted with clustered AChRs as well, 
showing that low-affinity IgG and IgM antibodies to AChR may be present in a few 
MuSK-MG patients (Leite et.al., 2008). IgG4 antibodies were previously known in 
autoimmune disease and thought to occur as a benign phenomenon in conjunction with 
resolution of allergic reactions. However, they are recognized in other diseases, such as 
forms of pemphigus (Huijberset.al., 2015). 
1.8.6 Other antibodies 
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LRP4 is as essential as MusK in the development and function of the adult NMJ, where 
it performs both anterograde and retrograde signaling roles (Fig 1.2; Koneczny et.al., 
2014). These roles highlighted LRP4 as a putative antigen of interest, and LRP4 
antibodies were reported in a small proportion of SNMG Japanese patients (Higuchi 
et.al., 2011) and more often in European patients (Pevzner et.al., 2012). The antibodies 
were of the complement-activating IgG1 type (Higuchi et.al., 2011) and impeded agrin- 
induced clustering of AChRs in one study. Agrin and Collagen Q, antibodies to agrin 
have been identified in a small number of ‘triple negative’ MG sera (samples negative 
for AChR, MuSK and LRP4 antibodies) at proportions from 15 to 50%, but these 
antibodies, usually at low titres, were often found also in patients with AChR or MuSK 
antibodies (Cossins et.al., 2012; Zhang et.al., 2014). ColQ localises the acetylcholine 
esterase within the synapse and is thought to interact also with MuSK. ColQ antibodies 
were reported in 3–4 %  of  all  MG  patient  sera  tested  but  only  5.5  %  of  the 
AChR/MuSK/LRP4 negative samples (Vincent et.al., 2018).  
 
1.9.1 Medical treatment of MG 
 
Treatment often relies on institutional preferences and the experience of the prescribing 
clinician as well as course of the disease. Below are listed various treatments for MG 
which are still non-specific till date. Acetylcholinesterase inhibitors are usually first line 
therapy, providing symptomatic relief in ocular and generalized myasthenia.  Side 
effects of acetylcholinesterase inhibitors are both muscarinic (abdominal cramps, 
salivation and lacrimation) and nicotinic (muscle cramps). Short term 
immunosuppression and long-term immunosuppression are dependent on prednisolone 
(Sathasivamet.al., 2008; Schneider-Gold      et.al., 2005)      and     azathioprine 
(Palace et.al.,1998) respectively. Long-term immunomodulation involves thymectomy in 
 
non-thymoma patients which has been shown to be effective (Wolfe et.al., 2016).  There 
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are a number of other drugs and they are described below. Therapeutic monoclonal 
antibodies are considered later. 
Patients with MuSK positive MG tend not to respond so well to acetylcholinesterase 
inhibitors and are more sensitive to their side effects (Kawakami et.al., 2011). The basis 
of this cholinergic hypersensitivity in MuSK positive MG is thought to relate to the 
interference of MuSK binding to Col-Q which leads to a reduction of 
acetylcholinesterase at the neuromuscular junction (Kawakami et.al., 2011). 
Corticosteroids: 
 
The majority of patients with generalised MG will require immunosuppression and 
patients with MuSK antibody positive MG may require early and aggressive 
immunosuppression. Corticosteroids are generally the first line immunosuppressive 
treatment. It is thought that early use of steroids in ocular MG may prevent 
generalisation (Monsulet.al., 2004). Azathioprine, methotrexate and mycophenolate are 
among the most frequently used oral immunosuppressant agents. 
Azathioprine: 
 
Azathioprine is one of the most widely used second line immunosuppressant agents. It 
has been shown in two randomized controlled trials to have a steroid sparing effect. The 
maximal efficacy of azathioprine treatment may only be achieved after one year of 
treatment (Palace et.al., 1998). 
Methotrexate: 
 
Methotrexate has also been recommended in MG by the European Federation of 
Neurological Sciences (EFNS) as a second line agent. It has been found to have a 
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Cyclosporine has been found to be effective. In MG in a small randomised trial and it 
has a fast onset of action compared to other steroids in MG (Tindall et.al., 1987). 
However, it was used only in particularly steroid-resistant cases. 
Cyclophosphamide 
 
Cyclophosphamide is an alkylating agent that is rarely used due to its adverse effect 
profile and is generally reserved for truly refractory cases of MG. It has been shown to 
be of benefit, showing marked improvement in myasthenic weakness in a small group of 
myasthenic patients (Drachmanet.al., 2003). 
Plasma Exchange and IVIG 
 
Plasma Exchange (PLEX) and intravenous immunoglobulin (IVIG) are treatments with 
a rapid but transient effect and are used in certain situations such as myasthenic crisis 
and rapidly worsening myasthenia (Newsom-Davis et.al., 1978). 
 
IVIG has been demonstrated to be effective for the treatment of worsening myasthenic 
 
Weakness (Zinman Ng, Brill., 2007), its mechanism of action is complex and involves 
inhibition of cytokine competition with autoantibodies, inhibition of complement 
deposition, interference with the binding of Fc receptor, and interference with antigen 
recognition by sensitized T cells. 
1.9.2 Thymectomy in the management of MG 
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Removal of the thymus gland, thymectomy, is a frequently used treatment for MG. 
There is a rationale for the use of thymectomy in non-thymomatous AChR antibody 
positive MG as the B cell follicles and the germinal centres of the thymic tissue are the 
likely site of antibody production. Since these early reports, thymectomy has become an 
accepted treatment for early onset MG. Non-randomized studies suggested that 
thymectomy was associated with an improvement in myasthenic symptoms and an 
increased likelihood of remission (Gronseth&Barohn., 2002). A recent randomized trial 
has shown that thymectomy combined with prednisolone, compared to prednisolone 
alone, does result in an improvement of myasthenic weakness, and allows a lower dose 
of prednisolone and enhanced quality of life by reducing symptoms and adverse events 
(Wolfe et.al,.2016). 
1.10.1. Therapeutic targeting of B cells 
 
Better treatments for autoantibody-mediated diseases require further work on the 
autoreactive B cells and antibodies that are involved in a variety of neurological 
diseases. Their causative roles have been formally established in some disorders and are 
likely involved in the pathogenesis of others. During the immune response against an 
antigen, B cells bearing antigen-specific receptors proliferate and differentiate into 
antibody-secreting plasma cells within the germinal centres. This requires the presence 
of follicular dendritic cells (FDCs) and activated CD4 T-helper 1(Th-1) cells, 
CD40/CD40 ligand interaction, and a cocktail of cytokines to create the 
microenvironment necessary for a germinal centre reaction. A few B cells bearing an 
appropriate antigen receptor are stimulated to undergo clonal proliferation in the dark 
zone of the germinal center and differentiate into centroblasts, centrocytes, memory B 
cells, and plasma cells. Antibody-secreting plasma cells migrate out of the follicle into 
the surrounding tissue (Stott et.al., 1998). 
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Several markers are expressed on B cells during their proliferation, differentiation and 
development, and help characterize them into subsets. CD 20, CD19, CD27 and CD138 
which are found on the surface of B cells and plasmablasts, are currently in research to 
develop B cell targeted immunotherapy to treat MG and other related autoimmune 
neurological disorders (Fig 1.5). 
1.10.2 Response of B cells to therapeutic abs 
 
Targeting surface antigens expressed on tumor cells and B cells, monoclonal antibodies 
have demonstrated to be effective as treatments in cancer and autoimmune diseases 
respectively. Recent successful antibody-based strategies have focused on enhancing 
anti-tumor immune responses by targeting immune cells, irrespective of tumor antigens 
or self antigens. 
Rituximab is a chimeric monocloncal antibody directed against CD20, a molecule 
expressed on B cells. It has an established role in the treatment of multiple sclerosis 
(MS). A number of retrospective studies have demonstrated its efficacy in MG (see 
Collongueset.al., 2012). It reduces circulating B-cell counts, and on the basis of its 
potential for targeting autoreactive B-cell clones, has a therapeutic role in antibody- 
mediated autoimmune diseases. It has been a useful treatment in IgG4-related diseases 
which eliminates a population of B or plasma cells responsible for the production of 
IgG4 antibodies (Huijberset.al., 2015). 
Ofatumumab, is a fully humanized monoclonal anti CD20 antibody which inhibits early 
B cell development. Ofatumumab induces efficient depletion of peripheral B 
lymphocytes in rheumatoid arthritis on retreatment after rituximab (Quattrocchiet.al., 







Figure 1.5 Naïve or memory B cells are activated by an antigen 
binding to surface IgG. The B cells proliferate and differentiate 
into effector B cells. The effector cells produce and secrete 
antibodies with a unique antigen-binding site, which is the same 
as that of their original membrane-bound IgG that served as the 
antigen receptors. (from Alberts B, Johnson A, et. al., 2002). 
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Its effect on B cells from MG patients’ thymus is currently under study. There are 
several emerging therapies for MG, including tacrolimus, antigen-specific apheresis and 
other treatments that await evidence of their efficacy and role in the treatment of MG. In 
addition, complement inhibitory therapy has been shown to be effective in experimental 
MG (Zhou et.al., 2007) and might prove promising in myasthenic crisis and particularly 
in ocular MG, because of the low expression of complement regulators in extraocular 
muscle (Kaminski et.al., 2004). Eculizumab is a humanized monoclonal antibody that 
cleaves the complement component C5 and hence blocks the formation of the terminal 
complement complex. (Howard et.al.,2013). 
Recent findings suggest that B cells have critical positive and negative roles in 
autoimmune disease (Matsushita et.al., 2008). Therapeutic strategies that specifically 
target AChR antibody-producing memory B cells would be a major advance, but for this 
it is necessary to identify and characterize the AChR-antibody specific B cells. 
The myasthenia gravis thymus includes germinal centres and immune cells that are 
involved in the pathogenesis of the disease, providing a potentially valuable source of B 
cell and plasmablasts that can be studied in vitro. 
1.11 Membrane vesicles used as an antigen 
 
Membrane vesicles (MVs) are released from different cells and are an emerging interest 
as biomarkers in a whole range of disorders. Classification, isolation, detection and the 
biological functions of membrane vesicles is still under investigation in these different 
fields (reviewed by Gyorgy et.al., 2011). The intracellular space of multicellular 
organisms contains solutions of metabolites, ions, proteins and polysaccharides. MEVs 
include exosomes, activation- or apoptosis-induced microvesicles, microparticles and 








Figure 1.6. Size ranges of typical membrane vesicles in comparison with 
viruses, bacteria and cells. Exosomes share size with viruses, 
microvesicles share with bacteria or protein aggregates and then largest 
is a cell. (from Gyorgy et.al., 2011) 
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The MVs to be used in this thesis lie between 100nm to 1µm and derive mainly from the 
cell surface membrane of transfected cells. 
Vesiculation may be classified as a type of trogocytosis. The transfer of membrane 
components between donor and acceptor cells was coined “trogocytosis” (from 
Greek“trogo”, meaning “gnaw” or “bite”). Some authors suggest that trogocytosis 
challenges classical theories of cell autonomy (Rechaviet.al., 2009), as cells may receive 
membrane and cytoplasmic fragments from other cells. Two forms of membrane transfer 
(trogocytosis) have been described: via nanotubes or via membrane vesicles (Davis, 
2007). This project focuses on membrane vesicles formed from the membrane of 
mammalian cell lines. The biogenesis of membrane vesicles essentially distinguishes 
exosomes from MVs and apoptotic bodies. 
Aim of the thesis: 
 
There were three aims of this study, 
 
1. To characterize AChR abs in MG sera and in their thymic suspensions for the 
selection of suitable patients for studying the synthesis of the antibodies. 
2. To produce AChR expressing membrane vesicles to restimulate antigen specifc 
B cells in the thymic suspensions. 
3. To identify B cells (memory B cell subset) which are specific for AChR 
antibodies using AChR membrane vesicles, as a source of antigen presentation 




Materials and Methods 
 
 
     2.1 Introduction 
 
Although much is now known about autoimmune diseases, more specific therapies are 
needed. This study aimed to characterise the B cells in myasthenia gravis in order to 
provide a more directed and cell-targeted approach to treat MG. 
To detect antibodies and their specificity, several tests are available including western 
blotting and, more recently, line blots, both of which use linear, denatured targets, and 
are often used to detect antibodies to intracellular targets. Newer assays have been 
developed that maintain the native structure of membrane proteins to permit detection of 
antibodies that recognize extracellular targets; specifically cell based assays (CBAs), 
radioimmunoprecipitation assays (RIPA), and fluorescence activated cell sorting 
(FACS). 
2.2 Patients providing serum and thymic samples 
 
Patients selected for this study were mainly seropositive Early Onset Myasthena gravis 
(EOMG), selected to cover a wide range of clinical parameters including age at the onset 
of disease/thymectomy, prior MG durations and AChR antibody titers. The origin, 
demographic and clinical details of patients were available from Prof Willcox but only 
the demographics are shown in Chapter 3. All samples were obtained with informed 
consent under approved ethical guidelines. 
 
2.3 Samples for analyses 
 
Serum samples were stored at --20oC, and thymic cells and thymic tissues from MG 
patients, thymectomized between 1970 and 2007, had been stored in liquid nitrogen 
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(LN2) by Prof Willcox and colleagues. None of the thymectomized patients had received 
immunosuppressive drugs or steroids before thymectomy. Blood samples of the patients 
were collected at regular intervals over the years between 1970 and 2007, before and 
after thymectomy, in order to measure the antibody levels in the sera. Some EOMG 
samples were plasmas obtained from anti-coagulated blood samples, and there was 
always some fibrin clot evident on thawing. These samples were centrifuged, and the 
supernatants transferred into clean tubes avoiding as much of the floating fibrin as 
possible. They were then carefully aliquoted into smaller tubes or vials, labelled, stored 
at -20oC and each vial used once only to avoid deterioration on further freezing and 
thawing. 
2.4 Preparation and transformation of E.coli for plasmid preparations 
 
This project started with CBAs of antibodies binding to AQP4 and AChR receptors 
expressed on human embryonic kidney 293T cells. AQP4 is a single subunit protein 
which has a single transmembrane protein and expresses well on the plasma membrane. 
Binding of antibodies can be detected easily and read with an immunofluorescence 
microscope. 
To provide cDNA for transfection, plasmids needed to be produced by highly competent 
 
E. coli cells, (JM109), a K strain that is recA and endA to minimize recombination and 
improve the quality of plasmid DNA. These competent cells were available as standard 
format 200µl aliquots provided by Promega. 
Five hundred mL of Luria Broth (LB) was prepared by adding tryptone (10mg/mL), 
yeast extract (0.5mg/mL), NaCl (0.5mg/mL) and agar (0.75mg/mL) to RNase free 
water. Broth was autoclaved and antibiotics, ampicillin (100µg/mL) and kanamycin 
(50µg/mL), were added. Broth was then poured into two different kinds of antibiotic 
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resistant petri dishes filling 3/4th of the dish, under the bacterial culture hood. Petri plates 
were separately marked with a red/black stripe indicating AmpR and a blue/black stripe 
indicating KanR. All the plates were left in the hood until dried completely. 
2.4.1. Isolation and preparation of plasmid DNA from E.Coli 
 
The different cDNAs for the AChR subunits and the clustering molecule rapsyn-EGFP 
were originally designed and produced by Prof. David Beeson et.al in the laboratory and 
were to be used for transient transfection of HEK cells. First, pcDNA 3.1 hygro 
(Invitrogen) and pEGFP-N1 were purchased from Clontech Laboratories, Inc. pGEM®- 
T Vectors provided by Prof David Beeson were used as they contain numerous 
restriction sites within the multiple cloning region (Fig 2.1). The pGEM®-T Vector 
multiple cloning region is positioned by recognition sites for the restriction enzymes 
EcoRI, BstZI and NotI, providing three single-enzyme digestions. These vectors have 
high copy numbers and contain SP6 RNA polymerase promoters positioning a multiple 
cloning region within the α-peptide coding region of the enzyme β-galactosidase. 
cDNAs for AChR subunits α, β, γ or ε, δ and rapsyn-EGFP were expressed by 
transforming pGEM-T easy vector containing pDNA into High Efficiency Competent 
Cells on the sterile agar plates. pDNA was diluted with RNase free water in the ratio of 
1:10, at an optimal working concentration of pDNA between 80-100 ng/µl. For each 
preparation, a single colony was used to inoculate 600 ml of Luria Broth (LB) and 
grown overnight in a shaking incubator at 37°C. cDNAs were purified using the 
Promega kit for Maxi preps (provided by Cat. L2001, Promega). DNA yield was finally 
measured using ND100 Nanodrop software, in nanograms. The optimum working 
concentrations of plasmid DNAs were 0.8-1.2 µg/mL. 
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2.5 Cell Culture techniques 
General conditions and reagents 
HEK 293T cells (human embryonic kidney), TE671 (human rhabdomyosarcoma with 
muscle like properties) and CN21 were grown in DMEM (Dulbecco’s modified Eagle’s 
essential medium, Sigma Aldrich, UK) supplemented with 10% fetal calf serum (FCS, 
HYclone, USA), with 100 units/mL each of antibiotics (A+A; penicillin and 
streptomycin from Invitrogen, UK). All the cells were cultured at 37oC in a humid 
atmosphere with 5%CO2. 
Examples of the HEK 293T cells are shown in Fig 2.2. The cells were split at around 
80% confluency. Culture medium was aspirated and the cells were detached by 
trypsinization (0.5% trypsin, 0.5mM EDTA, Invitrogen) at RT. Trypsinised cells were 
washed at 1500 rpm for 5 mins. Cell pellets were resuspended in culture medium 
(DMEM + FCS + antibiotics as above) and diluted 1:9 into the flasks for propagation. 
2.6 Thawing of cells 
 
Cryo-vials containing frozen cells including thymic cells and peripheral blood 
mononuclear cells (PBMCs) stored in liquid nitrogen were transported in dry ice for 
further use. Cells were thawed at 37 °C in a water bath in the cell culture hood. Culture 
medium (RPMI) was added dropwise into the vial up to 0.5 mL, and the content 
transferred into larger tubes containing 80-100µL of DNase for 300x 106 cells, followed 
by slow addition of more culture medium to the tubes until the volume reached 10 mL, 
taking around 3 minutes. Cells were further washed and pelleted at 1200xg for 7 
minutes, then re-suspended in complete medium (RPMI + 5%FCS + A+A) of 10 ml and 









Figure  2.1.  The  pGEM®-T  Vector System II. This contains JM109 
Competent Cells in addition to all of the pGEM®-T Vector System I 
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2.7 Enzymatic/mechanical disintegration of thymic cells 
 
Fresh thymus tissues were dispersed mechanically by chopping and passing through a 
1mm mesh. During the subsequent washing, clumps were pelleted by centrifugation at 
low speed (800 rpm) and the single cell suspension was washed once and the cells used 
as Thy conv (conventional thymic cells) and frozen in LN2 for future use. From some 
Thy conv samples, low and medium density fractions were separated by ficoll gradient, 
with recovery of 15% and 40% of the total of 300 ×106 cells. 
2.8 Splitting HEK293T, CN21 and TE671 Cell lines 
 
HEK cells were grown in the incubator at 37oC in 5% CO2 usually in (175 cm
2) culture 
flasks. When 80-90% confluent, the medium was aspirated under sterile conditions in 
the category II hood. 1 ml of 10 X trypsin in PBS was added to the cells carefully so  
that cells were not damaged. The flask was rotated gently, so that the trypsin solution 
covered all the cells, and after 1 minute the trypsin was discarded. The process was 
repeated with another 3 ml of 10 x trypsin. The cells were left for 30-90 seconds in the 
culture hood. Then, gentle rotation was applied to the flask until the cells could be seen 
beginning to detach from the plastic surface. The flask was tapped gently to dislodge  
the cells. 8 ml of fresh DMEM with 10% FBS/1xPSA or antibiotic/antimycotic was 
added. The medium containing cells was then transferred to 50 ml falcon tubes. Cells 
were centrifuged at 1100 x g for 4 minutes at RT. The supernatant was aspirated and the 
pellet was resuspended in 9 ml of medium in the same falcon tube. 1 mL containing 
around 0.45-0.50x105 cells of resuspended cells from the falcon tube were added to 39 
ml DMEM/10% FBS/PSA in a new 175cm2 flask. This method was optimized by 











Figure 2.2. Cultured HEK 293 T cells. As seen in a 175cm
2 
flask of cells 
grown in DMEM with FCS. B. HEK 283T cells taken 48 hours after 
first passage at the magnification of 40X under inverted microscope. 
Cells were usually harvested at 80% confluency for CBAs. 
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To obtain HEK 293T cells at high confluency for the following day, 3 ml/1.5 x 105 cells 
were added to a new flask with 25 mL of fresh culture medium in 175cm2 flask. Cells 
were transferred carefully to the incubator set at 5%CO2,37
oC. 
2.9. Preparation of cells for Immunofluorescence assay 
Transfection of cells for the expression of AChR and rapsyn: 
For transfections, HEK 293T cells at 80% confluency were washed at 1500 rpm and the 
pellet was re-suspended in 5 or 10 mL of culture media. These were then seeded at a 
concentration of 0.45 x 106 cells per well in 6 well plates pre-coated with poly-L-Lysine 
and with 4 plastic coverslips in each well and grown for 24- 30 hours under 5% CO2 at 
35oC. 
The plasmid DNAs were designed for transfections as described above. pDNAs for 
human adult and fetalAChR and rapsyn-EGFP were transfected at 3µg total DNA per 
well (dividing between α, β, δ, γ or ε, with rapsyn-EGFP) in 2.5 mL of DMEM with 1.5 
 
µL of transfecting reagent polyethylenimine (PEI). After 14-16 hours, the medium with 
 
PEI was discarded by carefully aspirating and replaced with fresh culture medium and 
 
the cells kept in the incubator for another 21-24 hours before use. 
 
Similarly, for MuSK and AQP4, HEK 293T cells were transfected as above with 3µg of 
 
each plasmid DNA per well using polyethylene imine (PEI). After 14-16 hours the 
 
medium was replaced with fresh culture medium and left for 21-24 hours in the 
 
incubator. After 24 hours, cells were ready for testing/immunofluorescence assay. 
 
Antibody testing using the AChR, AQP4, or MUSK transfected cells: 
 
The techniques used for measuring antibodies by CBA are shown graphically in Fig 2.3. 
Specific antibodies were identified in the sera of MG patients by immunofluorescence 
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cell based assay (CBA). Patients’ sera were diluted 1:20 and incubated with the cells for 
1 hr at RT before washing to remove any unbound antibody. The cells were then fixed 
with 4% formaldehyde for 5 mins and washed gently three times with DMEM only. 
After the third wash, fluorescent-labelled goat anti-human IgG (Alexa-Fluor 568 (red) or 
488 (green)) was incubated with the cells for 45 mins at RT or at 40C. After final wash 
with PBS, any cells with specific antibodies were identified visually by fluorescence 
microscopy using DAPI to identify the HEK cells. Sera of 10 patients, identified with 
high antibody levels were diluted in a serial order of 1:100, 1:200, 1:400, 1:800, 1:1600, 
1:3200 to check their antibody levels at highest dilution. 
Healthy control sera were from healthy laboratory individuals and were tested in 
parallel. After optimization all the sera were repeated in similar conditions to ensure 
accurate comparisons. 
2.10 Thymic cell cultures 
 
Thymic cells were cryopreserved in 5% DMSO with 50% v/v FCS and stored in aliquots 
in liquid Nitrogen (LN2, at -150oC to -190oC; usually set at -160oC), information 
provided by Prof. Willcox. The thymic cells were transferred to dry ice before thawing 
as described in 2.6. The live thymic cells obtained after counting on Neubaurer counting 
chamber were pooled and plated at 6 million cells per well in 24 well plates or 3 million 
cells per well in 200 µL in 96 well plates. Over the consecutive four weeks, a quarter  
(50 liters) of each supernatant was collected and replaced with the same quantity of  
fresh medium (RPMI+ 10% FCS + A+A + L-Glutamine) and the three supernatants for 
each condition pooled. During the first week, the supernatant was collected three times 
at two-day intervals to compare the antibody levels in the first week versus the 












Figure 2.3. Different techniques used to detect AChR antibodies in patients’ 
sera. A. RIPA shows patient IgG binds to 
125
I labelled AChRs and is 
precipitated by excess anti-human IgG. B. CBA shows AChRs expressed 
on HEK cells binds patient IgG antibody, which is then detected by Alexa 
fluor 568 anti-human IgG. C. Symbols used to show ab and antigens in this 
figure. Taken from Leite, Waters & Vincent, 2010. 
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Pokeweed Mitogen at 1/10 and 1/100 dilution were used to stimulate the cells and 
cycloheximide at 1/100 was used to inhibit the production of antibodies (cycloheximide 
is a potent inhibitor of protein synthesis whereas pokeweed mitogen stimulates 
proliferation and activation of B lymphocytes). AChR antibody in the supernatants was 
measured using 125I- labelled α-bungarotoxin AChR. 
A total of 10 patients’ thymic cells were cultured and their supernatants tested by CBA. 
Supernatants collected from thymic cell cultures were incubated in 150 µLs with the 
transfected HEK 293Tcells and binding of any antibodies identified visually under 
fluorescence microscope as above.  None of the cultures were positive by CBA and  
only three patient cultures, with some RIPA positivity (see below), were used for the 
subsequent experiments. Supernatant from thymic cell cultures of the 10 patients were 
selected on the basis of high antibody levels in sera CBA and RIPA. 
2.11 Radioimmunoprecipitation assay for AChR antibodies in sera or culture 
supernatants. 
The RIPA assay is illustrated in Fig 2.3. 125I-α-bungarotoxin AChR (RSR Ltd Cardiff, 
UK) was incubated with 5 µl of test sera and 50 µl of culture supernatants, in separate 
tubes, under cold temperature overnight. After 16 hours, normal human serum (to 
provide carrier IgG) was added, if required, and anti-human IgG (from RSR Ltd.) and 
left for 2 hours at RT. Any resulting complex of labelled receptor and AChR antibody 
were immunoprecipitated by pelleting in the bench centrifuge at 13000 x g for 5 mins, 
washed with PTx and counted on gamma counting chamber using 125I-α AChR protocol. 
Selection of the serum samples for serial dilutions was based on the high titres of 
antibody levels on CBA and RIPA. 
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2.12 Preparation, production and staining of membrane vesicles 
 
Extracellular membrane vesicles were obtained because they have been shown to 
express high levels of certain antigens such as AQP4, and could be used as a source of 
the proteins for further studies. Transfection of HEK293T cell line with the plasmids 
containing AQP4 or AChR subunit genes were performed as above to provide cells 
expressing the AQP4 or AChRs. After 4 days of incubation at 5% CO2 at 37.5°C, the 
supernatants were spun and suspended in 50 µL of PBS with100 mM sucrose + 0.02% 
of Sodium Azide (NaN3) + 1:100 protease Inhibitor cocktail (PI). To check for the 
presence of AChRs, the cells or vesicles were incubated with high titre serum and anti- 
human Alexa fluor 568 IgG (H+L) to detect antigen binding of patient’s antibody to the 
vesicles. The concentrated stock was preserved at -20 °C for future use. In some 
experiments, the vesicles were used fresh, without NaN3 or inhibitors added. 
Cell lysates with and without the expression of AChRs were prepared using HEk293T 
cells incubated for 1-3 days after transfection. The cells were detached from the surface 
of the flask by using RIPA buffer 1x solution which contains 150mM NaCl, 1.0% 
IGEPAL, 0.5% sodium deoxychelate, CA 630, 0.1%SDS, 50mM Tris and pH is 8.0.  
The suspensions were centrifuged at low speed at 800 to 1000xg and the nuclear debris 
discarded. 
2.13. Isolation of Peripheral Blood Mononuclear Cells 
 
Cells were separated from whole blood samples in heparinised tube obtained from 
informed consent healthy donors by density centrifugation over Lymphoprep which is a 
readymade endotoxin tested solution especially made to isolate PBMCs. The protocol 
was provided by company Axis Shield. 
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After washing with FACS buffer 0.5-1.0 x 105 cells/mL in a test tube were incubated for 
15 minutes with 20 μl of human Fc receptor binding inhibitor on ice, followed by buffer 
wash and subsequently stained with primary antibodies (fluorochrome labelled anti- 
CD3, CD19) at optimized dilutions. The samples were washed and followed by 
incubation with the secondary antibodies as listed in Table 2.2. After final washes at 
3500 rpm for 5 mins, the cells were resuspended in FACS buffer, called as staining 
buffer and the cells were fixed, kept at 40C in the dark, and analysed the next day or 
immediately after resuspension in 100 µL of FACS staining buffer. The results were 
analyzed using Summit software. 
The thawed thymic cells were stained on day 0 and analyzed using the same method as 
for PBMC. 
2.14 Western Blotting 
 
AChR specific membrane vesicles harvested after 4-5 days of transfection were tested 
by western blotting to check for AChR in the membrane or vesicle preparations. Lysates 
obtained from preserved AChR vesicles and freshly prepared cell lysates from AChR 
transfected HEK293T cells were obtained in volumes of 20uL and 50uL respectively. 
1:10 dilution of reducing agent and 1:4 dilution of loading dye were added for each gel 
electrophoresis well and proteins were denatured at 90oC for 5 mins. 10µL of samples 
were run in each well in 10 x sodium dodecyl sulphate buffer (ME-SDS) at 150 V for 
one and a half hour. The proteins were transferred to PVDF membrane in the presence 
of transfer buffer containing 1x methanol at 50 V for an hour and then blocked in 10% 
of non-fat milk with 0.1% of tween 20 in PBS for an hour at room temperature. 
Nitrocellulose membrane was incubated overnight with AChR β subunit cytoplasmic 
anti-mouse monoclonal antibody in (1: 1000 dilution), while shaking. After 12 hours of 
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incubation the membrane was washed thrice with 0.1% tween 20 in PBS and incubated 
with HRP conjugated secondary antibody (goat anti-mouse at 1:2000 dilution) for one 
hour at room temperature, while shaking, and washed three times. After the final wash, 
Enhanced Chemiluminescence (ECL) was used and the film was developed in the dark 
room. 
 
2.15 Flow cytometry 
 
For immunostaining of thymic cells and sorting of antigen specific B cells and 
plasmablasts by FACS, Raji cells, a cancer B cell line, was first used in order to set up 
the B cell detection analysis on the FACS analyser. Later the Raji cells were used as a 
positive control with HEK293T in one of the experiments. 
B and T lymphocytes from PBMC’s of healthy donors were analyzed on the FACS by 
labelling them with specific CD19, CD20 and CD3 fluorescently labelled antibodies. 
Anti-Fc block (20 µl/test) was first used to block the Fc receptors present on B cells and 
left for 20 minutes in cold. The same method was used for identification of B and T 
lymphocytes in thymic cultures. 
To try to identify AChR specific B cells, AChR transfected HEK 293T cells were used 
to provide AChR-expressing vesicles. The HEK cells were first transfected with EGFP 
(green) and IRES (red) and analyzed on the Cyan Analyser to check the expression of 
the DNA in the cell line. The lymphocytes were then pre-incubated with AChR-EGFP 
transfected HEK293T cells for 45 minutes or with AChR specific vesicles for 45 
minutes in different tubes. 
After a wash with staining buffer (human serum in PBS at 1:100 dilution) the cells were 
incubated for 30 minutes on ice with fluorochrome labelled cell markers (Becton and 
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Dickinson and Miltenyi biotech). Cells were washed and analysed on CyAn™ ADP 
Analyzer and AChR specific memory B cells were sorted with BD FACSARIA III. In 
some experiments the cells were fixed and resuspended in staining buffer and analysed 




Characterization of acetylcholine receptor antibodies in MG 
Introduction 
Antibodies to AChR in MG (sometimes called AChR-MG) have been recognized over 
many years and are important for the diagnosis of MG. The most commonly used 
diagnostic    technique    to    detect    AChR    antibodies    in    patient’s    sera    is   the 
radioimmunoassay (RIPA) (Vincent et.al., 1985). It is now based on a mixture of fetal 
and adult 125I-α–BuTx labelled AChR extracted in detergent from two human muscle 
cell lines, one expressing fetal AChR (TE671) and the other expressing mostly adult 
AChR (CN21). The assay does not distinguish between antibodies binding one or other 
of the two isoforms. Traditionally, RIA and ELISA are used to test for antibody- 
mediated diseases at the NMJ especially MG, but these techniques may limit the 
sensitivity of antibody detection as some antibodies bind poorly to the detergent- 
solublised AChR, and bind more effectively to the intact native receptors, expressed on 
the cell surface as they are at the NMJ. These limitations led to the development of 
assays specific for pathogenic extracellular epitopes, which are termed cell-based assays 
(CBAs). The expression of proteins on intact live cells avoids the detection of antibodies 
to intracellular epitopes, which are unlikely to be pathogenic. CBAs as diagnostic tests 
have now been developed for many different diseases at the NMJ and in the central 
nervous system (CNS), e.g. MG, neuromyelitis optica with AQP4 antibodies 
and limbic encephalitis with LGI1 antibodies (see Vincent et.al.,2011for a review). 
 
Past studies suggest that autoantibodies against AChRs were present in 85% sera of MG 
patients (Lindstrom et.al.,1976; Merriggoli& Sanders, 2009). The 15% of patients with 
generalized MG whodo not have AChR antibodies are often referred to as seronegative 
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It was previously hypothesized that clustering of the AChR might improve the detection 
of AChR antibodies. Cell based assays (CBA) were established to test the antibody 
levels against clustered AChRs and these can also be used for identifying IgG subclasses 
(Leiteet.al.,2008). These assays can also be modified to look for either adult or 
fetal AChRs in patients’ sera (Vincent et.al., 2012 Vincent et.al., 2018). Here the 
binding of antibodies to adult and fetal AChRs were studied in MG sera and 
supernatants from thymic lymphocyte cultures. 
3.1 Patient samples 
 
RIPA and CBA were both used for autoantibody detection. There were 210 sera 
available for testing but on the advice of Prof Willcox, only 55 were used in RIPA. 
These included 30 from whom he had thymic cultures. 20 samples from healthy 
laboratory individuals were used as healthy controls. For the CBAs, 146 sera samples 
were tested including 15 AChR positive sera from the laboratory routine diagnostics. In 
addition, 30 NMO-IgG sera (some negative, some very strongly positive) were used to 
set up the CBA. Table 3.1 shows the examples of the patients studied with their antibody 
test results. The patients were of all ages including a few children, but mainly EOMG as 
older patients are not usually thymectomised. From the clinical details available from 
Prof N Willcox, 80% of the early onset patients had thymic hyperplasia and 20% had 
thymoma. 
3.2 AChR identification on 125I-α BuTx through RIPA 
 
Fig 3.1 shows the results of the RIPA assy for AChR antibodies in 55 MG sera and by 




































Sera = MG patients (n=55) 
HC= Healthy controls (n=2) 
Positive control (n=1) 
 
Figure 3.1 Radioimmunoprecipitation assay for AChR antibodies. 
Immunoprecipitation of 
125
I-α-BuTx labelled AChR with sera from 55 MG 
patients and 2 healthy controls. A serum from routine clinical assay was 
used as positive control. The cut-off was based on the two healthy controls, 
and similar to that used in routine clinical assays. All but two of the 55 MG 


























Table 3.1 Patients samples used and AChR antibody results 
 
 
Patient Activity of 
AChR(cpm) 12000 
Serum 5 µL 
Activity of 
AChR(cpm) 12000 
Serum 1 µL 
AChR antibody 
CBA score 
Patient 1 1665 1392 4 
Patient 2 1579 1170 3.5 
Patient 3 7977 7399 4 
Patient 4 904 801 0 
Patient 5 2981 2019 3.5 
Patient 6 1676 679 3 
Patient 7 4944 3277 4 
Patient 8 4588 4345 4 
Patient 9 1907 1108 0 
 Patient 10 9199  3.5 
Patient 11 9936  3.5 
Patient 12 7317  3.5 
Patient 13 5078  3.5 
Patient 14 3473  3 
Patient 15 10365  4 
Patient 16 1004  0 
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control sera immunoprecipitated less than 200 cpm which was subtracted from all 
results for plotting. There was a wide range of antibody levels in the MG patients with 
two within the range of the healthy controls (apparently negative). 
3.3 Cell-based assays for AQP4, fetal and adult AChR antibodies 
 
To establish the CBA technique, the well-expressed antigen, AQP4, was used. cDNA 
for AQP4 was transfected into HEK 293T cells and 30 NMO sera were tested for 
antibody binding. The cells showed very clear binding of antibodies in many of the 
NMO sera (for examples with a range of scores, see Fig 3.2). With the strongest AQP4 
antibody serum, the fluorescence was so strong that some appeared to be intracellular 
but the linear membrane staining could also be clearly seen in Fig 3.2. Interestingly, this 
serum also bound to small vesicles between the cells; these are likely to be the 
membrane extracellular vesicles to be investigated in Chapter 4. 
For the AChR assays the CBAs used cells co-transfected with fetal or adult AChR 
subunits and rapsyn that clusters AChR at NMJ. This assay detected AChR antibodies in 
a few patients, earlier regarded as seronegative with conventional RIPA (Leite et al., 
2008). HEK cells were grown on glass coverslips in 6-well plates and then transfected 
with the appropriate adult and fetal AChR subunit DNAs and rapsyn-EGFP as described 
in Methods. 
The following day medium was changed, and binding of antibodies tested one day later. 
The live cells were exposed to the patient samples, before fixing and detection of bound 
IgG using anti-human IgG. All the 161 samples were tested by CBA and 10 HCs 
starting with 1:20 dilution of the sera. Fig 3.3A shows the high density of HEK293T 
cells identified by DAPI staining of the nuclei suggesting good cell survival. Fig 3.3B 









Figure 3.2. Binding of AQP4 antibodies from NMO patients’ sera detected 
using Alexa fluor anti-human IgG (red). Results show binding of four 
different sera, scoring from 0 (negative) to 4 (very strong). Binding is clearly 
on the cell membrane of the highly transfected cells. The strongest binding 
sample (score 4) includes also detects small particles around the cells (arrow), 

























Figure 3.3. Binding of antibodies to the AChRs on the extracellular domains of the 
membrane. Clustered AChR expression on the cell surface of HEK 293T cells. A. 
DAPI binding shows the live cells. B. Rapsyn EGFP (green) cells which 
demonstrates good transfection rates. C. Anti-human IgG Alexa fluor 568 (red) 
binds to IgG on the clusters of AChRs. D, E. Merged images of IgG binding to the 
AChR clusters on the membrane of the cells at 40X and 100X magnification. The 
HC serum (top) did not bind to the cells, whereas the MG serum bound strongly, 
scoring 4. 
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fluorescence of anti-human IgG demonstrating that some of the cells have astrong IgG 
antibody bound to the surface. Fig 3.3D and E show two examples of stronger IgG 
antibody (red) with merged green EGFP fluorescence. The very strong green cells often 
did not have detectable IgG bound, but many of the less strong EGFP-expressing cells 
showed multiple clusters of IgG on the cell surface. Green clusters seen at higher 
magnifications represent the rapsyn-EGFP that clusters the AChRs. 
The binding of the human IgG was scored on a range from 0 – 4 as shown in Fig 3.2 for 
AQP4 antibodies. The results of the AChR antibodies tested for binding to both fetal and 
adult AChRs (expressed independently but in parallel for testing) are shown in Fig 3.4A 
and C. Many of the MG sera showed very strong binding of antibodies (score 4). 
Healthy control sera showed no detectable binding and were scored 0 or 0.5, but a few 
of the MG sera were also negative on these CBAs. 
The CBAs could therefore be used to compare the antibody binding to fetal and adult 
AChR in MG patients. Although many sera bound strongly to both AChR forms the 
scores were not the same (Fig 3.4A), and overall, there were more high scores on the 
fetal isoform (p<0.001 student’s t test). Fig 3.4C, D shows the results from thirteen sera 
of thymoma MG patients. Although the average scores were a little lower than the non- 
thymoma patient scores all were positive with slightly higher scores for fetal AChR 
(p<0.035); this is illustrated by the frequency distributions that show that the peak 
thymoma scores are lower than the non-thymoma scores (Fig 3.4 B, D). 
3.4 Accurate AChR antibody levels in sera measured by CBA 
 
To identify accurate titres of the antibodies on the CBAs, the positive sera were tested at 
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Figure 3.4. CBAs for fetal and adult AChR antibodies in non-thymoma (A) 
and thymoma (C) patients measured by CBAs. Scores lie between 0-4, 
indicating low to high antibody level in MG sera. Score above 1 were 
considered positive and below 1 as negatives. Many of the sera had high 
antibody levels against both clustered fetal and adult AChRs, but a number 
of non-thymoma sera were negative or very low positive for both forms. 
The frequency distributions of the fetalAChR antibody scores are shown in 





































































































































































M G t e s t s e r a a t h i g h t i t r e s 
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Figure 3.5. Antibody titrations in selected sera. Antibody titres can be measured by 
the dilution at which the serum becomes negative (defined as score of 1). This end- 
point dilutions ranged between <1:20 (patient 4, (D) to >1:3200 (patient 12 (F)). 
The control serum run in the same experiments usually scored close to positive, at 


























































At 1:3200 dilution four of the sera shown still bound detectably to the cells, whereas two 
sera scored 0 at that dilution. On each graph the HC serum is plotted; this was unusual in 
showing a score of 1 to 0.5 at 1:20 (most HC do not bind detectably). Patients 1, 2, 10, 7 
and 12 showed high antibody levels with endplate dilutions (scoring 1) from 1:800 to 
>1:3200 (Fig 3.5). However, patient 4 did not have detectable antibody above HC 
3.5 AChR antibodies in thymic cultures 
 
Serum and cryopreserved thymic cells were provided by Prof N WIllcox. Fig 3.6 shows 
the serum AChR antibodies tested by RIA. Patients 3, 10, 12, and 15 had the highest 
RIPA results, and of these 10 and 12 had been strongly positive by CBA (Fig 3.5). 
Because of the number of archived samples available, however, the first cultures to be 
thawed were from Patient 2, 3 and 7. These were then cultured for 28 days pooling 
triplicate samples at weekly intervals. Cultures were either unstimulated, or treted with 
pokeweek mitogen (PWM) at two concentrations or cycloheximide (CHX) which was 
used to inhibit antibody synthesis and to provide a negative control. The supernatants 
collected after 7 days showed patients cells produced very little if any antibody detected 
by RIA. The results are shown in fig 3.7 and only patient 3’s cells showed some 
production of AChR antibodies, with 400 cpm immunoprecipitated compared with only 
50 cpm in CHX. Ten further thymic lymphocytes were thawed and cultured for four 

































Fig 3.6. The high positive samples on the CBA measured by RIPA. RIPA 
results from 16 samples were re-tested to compare with the CBA results. 
The highest RIPA results were found in samples 3,10,11,12,15. Samples 7, 
8 and 13 had intermediate binding. Samples 7, 10 and 12 had been highest 




























































































Patient 7 Thymic culture (weeks) 
 
Figure 3.7 Detection of AChR antibody by RIPA in culture supernatants 
of two patients. A. Patient 3 cultures produced some antibodies during the 
first week (around 350 cpm above the CHX (cyloheximide) contros, with 
decreasing amounts subsequently. B. Patient 7 produced very little, not 
clearly increased over the CHX of around 60 cpm. In addition, Patient 2 
cultures (data not shown) produced no detectable antibodies during the 
four weeks of about 50 cpm consistent with the very low serum levels 

























The ultimate aim of this chapter was to establish the thymic cultures in which to study 
the presence of B cells that were specific for AChR antibodies. Two different antibody 
assays were used to test the sera from patients whose sera and thymic cultures had been 
archived. Although the serum antibodies were high in around half of the patients studied 
in detail, the archived thymic cultures produced were small amounts of antibody and 
only two were considered suitable for further study. Nevertheless, the establishment of 
CBA for clustered AChR set the scene for the work that follows where the transfected 
cells were used to derive membrane vesicles expressing AChR for studying antigen- 
specific B cells. 
 
 
Cell-based antibody assays have been developed previously (Leiteet al., 2008). 
Antibodies binding to clustered AChRs on CBAs have improved the diagnosis of a 
proportion of previously AChR-Ab–negative patients because they detect antibodies in 
patients who are not necessarily positive in the RIPA where the AChR is in solution. 
This was not a specific problem with the sera tested here as almost all sera tested were 
positive by RIPA, but it was possible that the CBA would detect antibodies that bound 
to rapsyn-clustered AChRs that could be different to those found in the RIPA. 
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The MG antibodies were overall a little higher for binding to fetal than adult AChR. 
Testing for fetal AChRs specifically has been useful as these antibodies can be strongly 
associated with arthrogryposis multiplex congenital in babies born to mothers with (or 
sometimes without) MG (Riemersma et.al., 1997). Using the mouse model of maternal- 
to-fetal transfer of these antibodies established earlier, a potential drug was shown to 
reduce transfer of the AChR antibodies from mother to developing fetus; if further 
developed, this drug might provide a useful treatment for subsequent pregnancies in 
similar cases (Coutinho, Jacobson and Vincent, unpublished findings). These 
observations, as well as some earlier studies in AChR antibody–negative MG, 
emphasize possible functional and antigenic differences between fetalAChRs during 
development and adult AChRs in mature muscle, where they are strongly clustered at 





Placental transfer of maternal IgG antibodies to the fetus is an important mechanism that 
provides protection to the infant while his/her humoral response is inefficient. IgG is the 
only antibody class that significantly crosses the human placenta. This crossing is 
mediated by FcRn expressed on syncytiotrophoblast cells. There is evidence that IgG 
transfer depends on the following: (i) maternal levels of total IgG and specific 
antibodies, (ii) gestational age, (iii) placental integrity, (iv) IgG subclass, and (v) nature 
of antigen, being more intense for thymus-dependent ones. These features represent the 
basis for maternal immunization strategies aimed at protecting newborns against 
neonatal and infantile infectious diseases. In some situations, such as mothers with 
primary immunodeficiencies, exogenous IgG acquired by intravenous immunoglobulin 
therapy crosses the placenta in similar patterns to endogenous immunoglobulins and 
may also protect the offspring from infections in early life. Conversely, harmful 
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autoantibodies may cross the placenta and cause transitory autoimmune disease in the 
neonate (Palmeira et.al., 2012). As it was clear that adult form of AChR is replaced by 
fetal AChRs at the time of birth. henceforth this study also confirms the presence of fetal 
AChRs in adults with MG. 
 
 
Numerous immunohistochemistry studies have shown the presence of B cells and 
germinal centres or lymphocytic infiltrates in the thymus tissue and plasma cells of MG 
patients. It was shown that the thymic lymphocytes could produce AChR antibodies in 
Vitro (Vincent et.al., 1978; Scadding et.al., 1981). It was therefore very unfortunate that 
there was little AChR antibody present in thymic cultures from the archived samples 
examined here. This may be because of the very long years of liquid nitrogen storage 
and may be due to death of thymic cells as a result of moving them from liquid nitrogen 
at -135oC to -80oC freezers. 
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Identifying the antigen-specific B cells in the germinal centres and in the circulation is 
not easy if the antigen is a membrane protein which is normally expressed only in 
muscle, as it was shown in the fig 3.2. To do this for myasthenia B cells requires a 
source of AChR antigen that could be used to label the B cells and to separate them from 
other subset of B cells with other antigen specificity. Chapter 4 describes a novel 








Identification of the antigen-specific B cells is a necessary step in order to target 
treatments against the antigen-specific cells. Identifying the antigen-specific B cells in 
the germinal centres and in the circulation is not easy if the antigen is a membrane 
protein, as discussed in chapter 3. To do this for myasthenia gravis, a source of AChR 
antigen is required that can be used to label the B cells and to separate them from B cells 
with other antigen specificities. A potential source of AChR is extracellular membrane 
vesicles (EMVs) from AChR transfected HEK293T cells. 
Production of membrane vesicles as aEMVs from AQP4 transfected cells have been 
successfully used to detect antibodies to AQP4 and other neurological antigens (Vincent, 
Waters unpublished results) and can offer a potential new method for detecting patients’ 
antibodies. It was hypothesised that membrane vesicles from AChR- transfected 
HEK293T cells could contain enough AChR on their extracellular surface to identify B 
cells. 
EMVs are micro- or nano-sized particles released from the endosomal or plasma 
membranes of cells. Vesicles may deliver proteins, lipids and other signaling molecules 
to other cells. The structure, biochemical/biophysical properties, analytical techniques, 
and physiological/pathological roles of membrane vesicles have been extensively 
characterized (Tang Q et al.,2017).  Surface plasma extracellular vesicles are released 
by a variety of cells into the environment and membrane vesicles are shred 
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off from the plasma membrane of the cells expressing transiently transfected proteins 
(Vincent, Waters unpublished). The first step was to develop the techniques for 
preparing extracellular membrane vesicles (EMVs) from HEK293T cells expressing 
AQP4, which express the antigen very strongly, and then to apply the approach to 
EMVs from AChR-transfected cells. 
4.1 Expression of AQP4 on HEK293T cells and membrane vesicles 
 
To obtain AQP4-expressing EMVs, HEK293T cells were transiently transfected with 
DNA for AQP4, which well expressed (see also Fig 3.2). The cells were incubated with 
the AQP4-antibody serum (1:20) followed by secondary anti-human IgG (red). Fig 
4.1A-C shows the DAPI stained nuclei, and immunofluorescence staining shows 
localisation of AQP4 patient IgG (red) on HEK 293T cells. The merge shows variable 
binding to the cells, some very strong. 
The next step was to harvest membrane vesicles from the AQP4-transfected HEK293T 
cells, taken at later times to increase expression and EMV production, following the 
protocol described in the Methods (Chapter 2). 
4.2 Membranes vesicles expressing AQP4 
 
AQP4 membrane vesicles were harvested from the supernatants of AQP4 transfected 
HEK293T cells collected 2, 3 4 and 5 days after transfection. After a low speed spin to 
pellet the nuclei and large membrane particles in the supernatant, the AQP4 vesicles 
were pelleted at 30,000 rpm in the ultracentrifuge. The vesicle pellet was resuspended in 
50 l of PBS and 0.5 or 1 l spotted on to PLL coated glass slides and then allowed to 
















Figure 4.1 Immunofluorescence staining of HEK 293T cells expressing AQP4 
from patient with NMO. A. HEK293T cells visualised by dark field microscopy. 
A. Nuclei of the treated cells were stained with DAPI. C. Patient IgG binding to 
the cells as shown by red Alexa fluor anti-human IgG. D. IgG (red) binds only 
to a proportion of the DAPI labelled cells, probably limited by the transfection 
rate in this experiment. 
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cells produced a good yield of AQP4 vesicles within 4-5 days after transfection. Figure 
 
4.2 shows examples of membrane vesicles from cells transfected with AQP4 which were 
exposed to AQP4 antibody positive patient serum and the IgG bound identified with 
Alexa Fluor 488 (green) anti-human IgG. The vesicles typically spread to the periphery 
of the spot and there was a distinct band of green fluorescence around at the edge as 
seen in Fig 4.2. 
To confirm that the binding was specific for AQP4 antibody positive sera, Figure 4.3 
shows results of one healthy control serum and one AQP4 antibody positive serum 
binding to the vesicles. 
4.3 Production of AChR membrane vesicles 
 
The same approach was used to prepare AChR membrane vesicles. HEK293T cells were 
transfected with the adult AChR subunits together with EGFP-rapsyn. Figure 4.4a shows 
the very strong binding of AChR antibodies to the clustered AChRs on the surface of the 
HEK cells. The vesicles prepared from these cells are shown in Figure 4.4b. There is 
nuclear material (DAPI stained) within the EMV spot co-localising with EGFP-rapsyn. 
The patient’s AChR antibody did not show strong binding although there was a faint 
suggestion of binding on the merge (Figure 4.4bD). 
To try to improve the AChR membrane vesicles, in some preparations AQP4 was co- 
transfected with AChRs to see if it would increase the yield of membrane vesicles. 
Results of experiments, conducted on fresh vesicles and run with the same HC and MG 
serum in parallel, are shown in Fig 4.5. Control vesicles showed only faint IgG (red) 
binding at the periphery, as did healthy control serum suggesting some non-specific 
binding of anti-human IgG to the vesicle preparation rim (Figure 4.5A,B). AQP4 
antibodies bound well to AQP4 vesicles (Figure 4.5C). AChR antibodies bound 
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Figure 4.2 Vesicles prepared from AQP4-transfected HEK293T cells bind AQP4 
antibodies. 0.5 µl of AQP4 vesicles were spotted onto glass slides. The microvesicles 
tend to spread to the periphery of the droplet. After drying the slides, AQP4 antibody 
positive serum was added at 1:20 and binding detected with 488 goat anti human 
(green) antibody. A shows vesicles from untransfected cells. B, C and D show AQP4- 






























Figure 4.3. AQP4 vesicles stained with healthy control and patients’ sera. a, b shows 
staining DAPI indicating some nuclear material in the vesicle rim. c, d shows vesicles only 
without serum. e shows HC serum IgG does not bind to AQP4 vesicles, whereas f shows 
patient’s serum binds to vesicles. Binding detected by Alexa flour 568 (red). Pictures are 






Figure 4.4a. HEK293T cells transfected with AChRs with EGFP tagged rapsyn 
show clusters on their surface. A. DAPI stained nuclei. B. EGFP expression 
shows clustering of the rapsyn in the cells. C. MG patient antibodies show 
strong binding to the AChRs in a clustered pattern. D. Merged image 
 
A B C D 
 
 
Figure 4.4b Membrane vesicles expressing EGFP co-transfected with adult AChRs. 0.5µl 
droplet of vesicle suspension on a glass slide covered with a glass coverslip. A. DAPI 
shows nuclei material present in the vesicle suspension. B. Vesicles contain EGFP but no 
binding of IgG (C) IgG on the periphery, not clear. D. merge showing vesicle rim and no 
strong binding. 
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DAPI EGFP IgG MERGE 
A. Control vesicles - no AChR with HC serum 
 
B. AChR vesicles with HC serum 
 
C. AQP4 membrane vesicles with AQP4 serum 
 
D. FetalAChR membrane vesicles with AChR serum 
E. Adult AChR co-transfected with AQP4 with AChR serum 
 
F. AChR with AQP4 serum 
 
G. Alpha subunit of AChR with AChR serum 
Figure 4.5. The images of parallel experiments performed using different transfections 
to generate membrane vesicles. A. Control HEK vesicles and control sera provided 
negative controls. B. AChR vesicles tested with HC serum show no binding. C. AQP4 
vesicles incubated with AQP4+ serum show strong binding. D. Membrane vesicles 
expressing fetalAChRs bound AChR+ patients’ serum. E Vesicles from cells transfected 
with AQP4 andAChR bound AChR+ serum. F. However, AChR vesicle bound AQP4+ 
serum although not in the same manner as those above. G. Vesicles from cells only 
transfected with α subunit of AChR (no EGFP) were negative with AChR MG+ serum. 
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well to fetal AChR vesicles and also to adult AChR co-transfected with AQP4 to 
increase vesicle formation (Figure 4.5 D,E), but AChR antibodies appeared to also bind 
to AQP4-transfected vesicles (Figure 4.5F). On the other hand, AChR antibodies did not 
bind to alpha subunit transfected EMVs (Figure 4.5G). 
Membrane vesicles expressing the fetal form of AChR appeared to bind AChR 
antibodies more strongly than the adult form but a strict comparison was not made. 
4.4 Identification of AChR proteins in vesicles on western blots 
 
To try to confirm the presence of AChRs membrane vesicles in the pellet, western 
blotting and flow cytometry were performed. AChR membrane vesicles in the 
suspension were denatured and run on the gel electrophoresis. The blotted membrane 
was incubated with a monoclonal antibody to the AChRβ subunit followed by washing 
and incubation with secondary anti-mouse IgG antibody. Bands after the exposure to 
ECL demonstrate the proteins present in the test samples. Figure 4.6 shows binding of 
the monoclonal antibody to band at around 40KDa in the AChR HEK cell lysate and 
very strong binding to bands in the range of the AChR subunits, especially the β subunit 
(45 – 50 KDa) and to other bands in the two lanes containing membrane vesicles (Figure 
4.6, lanes 4,5). Figure 4.7 shows the relationship between protein bands and binding of 
the monoclonal antibody. The Coomassie stain shows many protein bands in the AChR 
cell lysates, as expected with no clearly specific bands in lysates or the EMV 
preparations. However, after transfer to nitrocellulose and blotting with the β subunit 
antibody bands at 45 and 48 KDa were present. However, the presence of other bands 
detected by the β subunit antibody or perhaps by the anti-mouse IgG secondary 


































Figure 4.6. Western blot to detect AChR in vesicles. Lane 1 is HEK cell lysate 
control with no detectable band present. Substantial binding of AChR 
antibody to lines 3, 4 and 5. The blot was incubated overnight with β 
cytoplasmic antibody and polyclonal anti-mouse IgG as a secondary to detect 
the bands. Protein bands prominent at around 40 KDa were expected to be  
the β subunit of AChRs. 
 
Lane 1, HEK cell lysate, lane 2, blank, lane 3, AChR HEK cell lysate, lanes 4 
and 5 membrane vesicles from AChR expressing HEK 293T cells. 
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Figure 4.7. Coomassie stain and western blot of AChR vesicles, produced from 
HEK293T cells. 4 wells were used first two for AChR lysate as a positive control and 
last three for AChR membrane vesicles. On exposure to ECL on different time scale, 
blots show bands of AChR proteins in the lysate and vesicles. Control and ladder do not 
show any band on the blot. Lane 1,2 ladders, lane 3 control, lanes 4,5 AChR cell 
lysates, lanes 9, 11, 12 AChR vesicles. Lanes 6,7,8,10 nil. 
1-minute exposure 
20 seconds exposure 
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antibody, or perhaps by the anti-mouse IgG secondary antibody, were disappointing. 
Unfortunately, no control antibodies were used to show the specificity of the beta 
subunit antibody but the binding to only three bands on AChR lysate, compared with the 
large number of proteins in the lysate shown on the Coomassie, suggested that the 
binding could be relatively specific. The 20s exposure of the blot shown expanded 
below emphasises this point. 
On further optimization of the western blotting method, increasing the washing steps 
and incubation time with the primary antibody, the results were better showing a single 
band of around 41 kDA in the lysates and slightly stronger in the EMV preparations, 
with no other bands (Figure 4.8). 
4.5 Identification of membrane vesicles by flow cytometry 
 
An alternative technique to detect AChR in vesicles, was FACS. Using freshly prepared 
vesicles, flow cytometry (Fig 4.9) revealed evidence for EGFP in the vesicle 
preparations, although the scatter in Figure 4.10 shows very little and mainly in the adult 
AChR-transfected vesicles. 
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Figure 4.8 Improved western blot of AChR. 41 kDa bands consistent with AChR beta 
(β) subunit are seen in lanes 4, 5, 6, 9 and 11. Proteins were incubated overnight with β 
cytoplasmic antibody and anti-mouse as a secondary ab to detect the antibody binding. 
Lane 1 blank, lane 2 ladder, lane 3 control vesicles no AChR protein, lanes 4,5, 6 AChR 

















Figure 4.9. Flow cytometric analysis of EGFP AChR vesicles. X- axis is FITC 
channel and y-axis is counts per test. A. Control vesicles do not contain significant 
EGFP expressing vesicles. B. EGFP positive vesicles shown by right shift increased 









Figure 4.10. Flow cytometric analysis of membrane vesicles showing EGFP. R1 
gate shows no colour. Autofluorescence is compensated. Surprisingly, only the 
adult AChR EMVs with and without AQP4 co-expression showed a faint signal in 
the FITC panels. In this experiment fetal AChR showed less detectable vesicles 
compared with adult AChRs, not very different from the controls. 
Control 
 AChR (fetal) EMVs with EGFP 
 
AChR (adult) EMVs with EGFP 
AChR (adult) + AQP4 EMVs 
Non-clustered AChR EMVs no 
EGFP 




The aim here was to prepare AChR membrane vesicles for use as a source of intact 
AChR antigen for detecting AChR-antibody specific B cells. The immunostaining 
results were variable and western blotting did not always show a band of the appropriate 
size for the beta subunit. However, there were some encouraging results. 
While optimizing the technique for preparation of the vesicles, there were important 
aspects to consider such as the centrifugation speeds used for pelleting the nuclei, and 
then for pelleting the vesicles. Preparation started with AQP4 because it is a single gene 
product and is expressed strongly on the plasma membrane and the cells shed off EMVs 
into the medium within 3-4 days after transfection. In fact, some vesicles were 
apparently present around the cells (as shown in Figure 3.2). The AQP4-vesicles gave 
convincing staining with AQP4 antibody NMO serum. A single  subunit of the AChR 
was a suitable negative control as it is not expressed on the surface of the cells or on any 
vesicles.as shown here. It is not suitable, however, for B cell identification in future 
studies because, although it contains the “main immunogenic region”, this is a very 
conformational epitope and is not present on the alpha subunit alone which is, in 
addition. 
The question of whether there is sufficient AChR expressed on vesicles, unlike AQP4, is 
still not clear. Overall, the results were variable for clustered and non-clustered AChRs 
(ie without rapsyn-EGFP) and for fetal and adult AChRs, although fetal AChRs tended 
to give more encouraging results in some WB and immunostaining tests. These fetal 
specific clustered AChR vesicles showed positive staining by immunofluorescence and 
apparently specific antibody binding of the monoclonal  subunit antibody on western 
blots, but adult AChR vesicles were also convincing in some experiments. Vesicles are 
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micro to nano particles which are shred off by the plasma membrane of large cells. PBS 
proved to be a suitable solution to preserve vesicles and no azide or similar preservatives 
were added as those had been shown to be toxic to the vesicles. From that study, 
membrane vesicles preparations should be used within a week. Alternatively, it might be 
possible to use the vesicles if frozen at -80 oC for up to one month. 
Staining of vesicles followed CBA methodology where washing of spotted vesicles was 
considered an important step to get rid of the non-specific binding of patients’ sera and 
IgG. Unlike AQP4 vesicles, AChR preparations did not show specific binding on 
immunofluorescence staining. Flow cytometric results demonstrated the presence of 
EGFP in the preparations but not the AChRs as clusters. Western blotting with the beta 
subunit antibody but to a certain extent it proved that the membrane vesicles should  
have AChRs, as hypothesized and a bit of work was done in the past on this specific 
monoclonal antibody against β. Highly specific technique to prove AChR membrane 
vesicles or other antigen in the suspension is CBA where AChR antibody should bind to 
IgG. From these results the best preparation and methodology was set as the protocol for 
future preparations. 
Although it was not that clear membrane vesicle staining with antibodies was entirely 
specific, considering the western blotting, the membrane vesicles were taken forward for 
the antigen presentation as described in the next chapter. 
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                                                                     CHAPTER 5 
 
Characterization of antigen specific B cells in MG thymus. 
 
The aim of this chapter was to identify antigen-specific B cells in the thymic culture 
supernatants. 
The normal role of the thymus is to develop mature T cells that are not self-reactive. 
However, in myasthenia gravis, plasma cells are present in germinal centres in the 
thymus and produce antibodies against AChRs, which are then circulated to the 
neuromuscular junction. AChR antibodies lead to complement mediated lysis and 
internalisation of the receptors, as mentoned in the Introduction. Depletion of AChR- 
specific B cells, or AChR-antibody producing plasma cells, is a major goal for 
treatment. B cells pass through various developmental stages before and after exposure 
to antigen. These stages are defined by differential expression of surface and 
intracellular markers, as well as their immunoglobulin secretion. After antigen 
presentation B cells become antibody secreting cells (ASCs) called as plasmablasts or 
plasma cells. The aim of this work was to use AChR-containing membrane vesicles to 
try to isolate the B cells that will become the AChR antibody secreting plasma cells. 
5.1 Identification of B cells and its subsets in Raji cells 
 
 
To identify B cell subsets, especially memory B cells and plasma cells, first Raji cells 
were used to establish flow cytometric analysis. The Raji cell line is a B cell expressing 
cancer line which is easy to maintain and was particularly suitable for the initial 
experiments. 
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The Raji cells are grown in suspension and take time to reach 80%confluency. The cells 
were cultured from 7 days to 14 days but usually the cells could be used on the seventh 
day. 50,000 cells were used for each test. Figure 5.1A-D shows the presence of APC- 
labelled CD19+ B cells, but not CD3+ T cells or CD138+ plasma cells. Figure 5.1E-F 
shows the presence of CD27+ B cells and thei co-expression of CD19 and CD27 on 
these cells. These results demonstrated that the FACS methodology was suitable and 
that B cells could be identified in preparations of PBMCs and thymic cultures. 
5.2 Analysis of B cells in thymic cells and peripheral blood mononuclear cells 
 
In all analyses, the control cells were unstained cells, If multiple types of cells were used 
then the controls were adjusted accordingly. The compensation of multiple 
fluorochromes at the start of each analysis was done on the controls followed by sample 
tests. The first experiment compared thymic cells with PBMCs. 
In Figure 5.2 A the controls were unstained thymic cells or PBMCs shown in separate 
windows. The PBMCs clearly contained two populations of cells expressing CD3 and 
CD19 respectively. Thymic cells were fewer in number than freshly isolated PBMCs as 
expected and did not appear to contain two populations but some that co-expressed both 
markers. This could be because they were freshly thawed (only 12 hours post thaw).  
The thymic cells were subsequently cultured for at least 2 days before testing. 
In Figure 5.2 B the cells were incubated with EGFP vesicles. There were two peaks of 
vesicles in the PBMC preparation, and the added vesicles were also seen in the thymic 






A. Control (negative) no 
B. CD19+ B cells APC 
 
C. CD3+ T cells PE labelled as a negative 
D. CD138+ Plasma cells as a negative control Per-cp labelled 
 
 
Figure 5.1 Shows presence of CD19 and CD27 expression as markers of 
B cells on Raji cells. Anti-human-CD3, a T cell marker and CD138, a 
plasma cell marker, were used as negative controls. Non-specific 
binding for fluorochromes were compensated for APC, PE and PerCP in 
control tests. A. Gated population on unstained cells on FS/SS shows no 
evidence of fluorescence in control sample. B. APC count shows high 
proportion of CD 19+ B cells in the Raji cells suspension as expected. 
C. Negative control. Showing no CD3+ T cells in the suspension. D. 
Shows lack of CD138- plasma cells in the suspension, as a negative 
control. Cont. overleaf. 
labelled 
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E. CD27+ B cells as a positive control PE labelled 
 
 
F. CD19+ and CD27+ B cells 
 








Figure 5.1 continued E. CD27+ staining showing a shift of the B cells in the 
suspension F. CD 19 and CD 27, B cell markers shows positive population. 
G. Shows that the CD19 and CD27 positive cells and negative for CD138, as 
expected. 
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Figure 5.2. Identification of cells in PBMCs and thymic lymphocyte 
preparations. A1 Unstained thymic cells on forward and side scatter. A2 Shows 
anti-CD19+ B cells on x axis and anti-CD3+ T cells on Y-axis in PBMCs. A3 
shows that there are insufficient CD3+ and CD19+ cells in the thymic 
suspension. B1. Unstained thymic cells with EGFP vesicles. The cells were first 
gated. B2. Two significant peaks on the graph showed CD19+ B cells and 
EGFP vesicles in the PBMC suspension. B3. Shows EGFP vesicles on the x- 
axis but few APC-labelled anti-CD19+ B cells in the same thymic suspension. 
The R3 gates show that some EGFP vesicles were present with the CD19 B 
cells. 
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5.3 Flow cytometric analysis of CD19+ B cells and CD138+ plasma cells in thymic 
lymphocytes. 
After optimization of the method the B cell subsets were first identified in the thymic 
pool of cells from selected patients that had high levels of AChR antibodies in their sera. 
The cells of two patients (nos 3 and 7 in Chapter 3) were stained with CD20 and CD138 
 
markers to sort B cells and plasmablasts. CD20 is present on B cells but not plasma 
 
cells, whereas CD19 is more specific to memory B cells. These patients’ thymic 
 
populations showed the presence of CD19 B cells but no CD138 plasma cells (Fig 5.3). 
 
CD138+ cells were not expected to be produced in the thymic culture within 12 hours 
 
and without any re-stimulation by antigens. The results for patient 3 were expected as 
 
the cultures had produced some AChR antibody but were surprising for patient 2. 
 




A more detailed analysis of CD19+ B cells on PBMCs is shown in Figure 5.4. Figure 
5.4A shows the controls, 5.4B shows the CD19+ cells and C shows the CD3 cells.  
These experiments used 106 cells for each test (per test tube). These experiments helped 
to set up the tests on thymic cells. As thymic cells were precious and were not available 
in abundance, use of PBMC and other cell lines saved the extra usage and developed a 
protocol which was ideally suited on thymic cells, will be described further in the text 
and experiments. As PBMC and thymic cells shared the T cell and B cell development 
stages, it was beneficial to start experiments with human PBMC and then moving on to 
precious archived preparations from thymic cells. 
PBMCs were easier to handle and cell subsets were easily identified with the help of 
surface markers whereas thymic cells were clearly more difficult to deal with due to the 










Figure 5.3. Flow cytometric analysis of thymic cells in suspension. Thymic cells 
of patient 2 and 3 (from table 2 in chapter 3) labelled with anti-CD19, anti-CD20 
and anti-CD138 to look for plasma cells. . CD19 positive population were 
significant present in R2 , but there were no  apparent  CD138  plasma  cells. 
These samples were tested 12 hours after thawing. 
A Patient 2 CD19+ 
B Patient 3 CD19+ 
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Figure 5.4. PBMCs obtained just after 
isolation from whole blood, stained with 
fluorochrome. APC labelled anti-CD19 
for B cells and PE anti-CD3 for T cells 
as a control. CD19 positive and CD3 
positive population of cells were 
identified in the cell suspensions. 
A.1,2,3,4,5,6,7 Control, unstained cells 
shows no expression of fluorochromes 
on the cells. Continued overleaf. 
7 
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Figure 5.4 continued. B. 1,2,3,4, APC labelled anti-CD19 antibody shows 
CD19+ population of B cells as expected. C. 1.2.3.4 PE labelled anti-CD3 







D. APC CD19+ and PE CD3+ PBMCs 
 
 
   
 
 
Figure 5.4 continued. D. 1,2,3,4,5,6 shows CD19+ B cells and CD3+ T cells in the 
PBMCs. D6. clearly identifies CD19+ B cells and CD3+ population T cells in the 
suspension. 
1 2 3 
4 5 6 
89  
thymic cultures, the experiments were performed after 1 day of culture. In this case, 
CD3+ and CD19+ cells were identified as two populations (Figure 5.5). 36 hours after 
thawing, a small population of CD138 plasma cells were detected in the R11 and R12 
gates. (Figure 5.6). 
5.4 Selection of antigen re-stimulated B cells from the thymic lymphocytes of MG 
patients producing antibodies at high titres in sera 
Thymic cells were incubated with AChR EGFP vesicles to try to identify antigen 
specific B cells in the pool. The cells were stained with anti-CD19, anti-CD3, ant-CD27 
and anti-CD138 as above. In this case the patient whose cells were tested had high titres 
of AChR antibody scoring 3 at 1:1320. The results showed B cells in the thymic cultures 
as before with no detectable change in the presence of control vesicles. The thymic cells 
were incubated with AChR-EGFP vesicles for 30 minutes at 4ºC, to try to identify 
antigen specific B cells. The results (Figure 5.7F) show some co-staining of the APC 
CD19+ positive cells with the vesicles (Fig 5.7). CD3 T cells were not tested in last 
experiment mentioned above as it is a negative control in all the experiments. CD3+T 
cell marker helps to sort the T cell population from the pool which makes it easier to 
identify B cell population and specifically antigen specific B cells when restimulated 
with the specific antigen, in this case AChR membrane vesicles.  
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1. stained 2. log graph 3. scattering 
 
A. Unstained cells in thymic pool 
 
B. PE CD3+ cells in thymic pool 
 
C. APC CD19+ cells in thymic pool 
 
 
D. CD19+ B cells and CD3+ T cells 




APC = CD19 B cells PE = CD3 T cells 
Figure 5.5. Anti-CD3 and anti-CD19 detect T and B cells in the suspension of 
thymic lymphocytes after culture for 1 day. A.1,2,3 Control shows unstained thymic 
cells. B. 4.5.6. PE CD3 Show CD3+ T cells in thymic culture. C. 7,8,9, Shows APC 
CD19+ B cells. C9 shows Y-axis has a number of CD19+ B cells on its axis. D. 
10,11,12, Combined plots of two different populations of the cells. D 

















Figure 5.6 Gated population shows CD138+ cells in the thymic 
suspension. On FITC log CD138+ cells are visible. This test was 
conducted after 36 hours of thawing of cells and after incubating with 
AChR vesicles (no colour) for 30 minutes. On plots 2 and 3 CD138+ 
plasma cells are shown in lesser number, as expected. The peak on plot 2 
shows nearly 100 CD138+ plasma cells in the gate, and on plot 3 in the 




















B. Control unstained vesicles 










C. APC CD19+ B cells in thymic pool 











Figure 5.7. Thymic cells incubated with AChR EGFP vesicles. Anti-CD19 was 
used to identify antigen specific B cells. Anti-CD3 was used to sort T cell 
population from the pool as a negative control. A.1,2,3 Control compensates the 
auto fluorescence for all the fluorochromes used in each test. B.4,5,6, Unstained 
membrane vesicles were used to compensate for the autofluorescence, cells 
unstained. C.7,8,9 APC anti-CD!9 marker was used to sort the CD19+ B cells 
from the suspension, C9 plot shows some CD19+ cells on the x-axis. Cont. 
overleaf. 
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A successful B-cell response to an antigen involves the development of two distinct B- 
cell types, memory B cells and plasma cells. Memory B cells are long-lived and rapidly 
mount a secondary antibody response upon re-exposure to the corresponding antigen. 
Plasma cells secrete large amounts of antibodies spontaneously and die after a few 
weeks. However, an exceptionally long-lived subpopulation of plasma cells migrates 
into the bone marrow where it produces high-affinity Immunoglobulins for years. 
(Archelos & Hartung, 2000). In the hope of identifying AChR antibody specific B cells 
in the thymic lymphocyte populations, that had previously been shown to produce 
AChR antibodies (e. g Scadding et al., 1981), the AChR-containing vesicles produced in 
Chapter 4 were tested. The methodology and approach followed was reproducible hence 
proving hypothesis right however, the results were satisfactory and need further 
development. 
To establish the techniques for identifying the thymic lymphocyte subsets, initial studies 
focussed on Raji cells and PBMCs. No AChR vesicles could be detected binding to 
healthy PBMCs but there was some evidence of AChR vesicles binding to B cells in the 
thymic pool. Due to the uncertain results partial of AChR membrane vesicles, the sorted 
B cells could not be characterized at a single cell level. but further studies improving the 
expression of AChR in the vesicles could lead to a way of specifically identifying the 
cells responsible for producing AChR antibodies in MG. It might be advantageous to try 
first with AQP4 B cells and plasma-blasts since the AQP4 is very well expressed in the 
vesicles and B cells producing antibodies have been cultured from NMO PBMCs 
(Wilson et al.,2018). 
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Raji cells were the easiest to set the standard protocols. On further study, PBMCs of 
controls were used before moving to the very precious thymic cells which were frozen 
by Prof Willcox in the past. The hope was that culturing thymic cells and then 
presenting them with the prepared AChR membrane vesicles at 4oC would demonstrate 
the binding of the EGFP-labelled vesicles binding to B cells and plasma cells. However, 
plasma cells were very rare even in cultures with (previously) high synthesis of AChR 
antibodies. The absence of fresh prepared thymic cells, as were used for the original 
studies of Prof Willcox, was a limitation of the study. 
The hope was that AChR-vesicle-identified B cells could be isolated by FACS, 
restimulated with the AChR-vesicles and antibody genes amplified using RT- 
PCR/nested PCR so that the variable H+L chains could be cloned into expression 
vectors for production of highly specific, patient derived antibodies. Another aspect of 
the work potentially would be to find ways of specifically deleting the AChR-specific B 






MG is an autoimmune syndrome caused by the failure of neuromuscular transmission, 
which results from the binding of autoantibodies to proteins involved in signaling at the 
NMJ. The endplate potential is insufficient to reach the crucial firing threshold, resulting 
in weakness at rest and/or increasing fatigue during sustained efforts, affecting any 
muscle group (Vincent., 2008). Generalized MG patients can be further subdivided on 
the basis of their thymic pathology and age at onset (Compstonet.al., 1980). 
Nevertheless, despite these clearly different pathological and genetic associations, the 
AChR antibodies themselves do not differ significantly between the subgroups, 
suggesting that the antibodies are the common final pathway that can be reached by 
several different aetiological routes (Vincent et.al., 1998). 
 
In most EOMG patients, the thymic infiltrates include numerous germinal centers 
(Willcox et.al., 1984), many of them contain autoreactive T- and B-cells along with 
terminal plasma cells that produce AChR antibodies (Shionoet.al.,2003). Several lines of 
evidence indicate that B cells, plasma cells, and, in particular, antibodies contribute to 
development and progression of MG. The aim of this thesis was to develop a novel 
approach to identify the B cells and perhaps early plasmablasts in patients with 
myasthenia gravis, by using AChR-specific EMVs. Unfortunately, despite some 
evidence that the technique could work, the cultures available and the results were not 
yet sufficiently robust to provide the basis for further development. 
 
This study had both advantages and limitations. First, the presence of archived sera and 
of thymic cultures stored in liquid nitrogen made it possible to do the project on samples 
that had been shown previously to synthesis AChR antibodies. Howevver, the lack of 
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fresh samples were a considerable disadvantage as the production of AChR antibodies 
by the cultures tested here was very poor (and also found by an Oxford DPhil student, 
ZZ). The amount of thymic cells obtained after thawing was very limited in number 
compared with the numbers frozen at the time of storing. When comparing with fresh 
PBMCs, it was very clear that use of fresh thymic cells would have given better yields 
of cells and made it easier to identify and target B cells and plasma cells in the cultures. 
Nevertheless, it was hoped that archived preparations could still be used to establish the 
approach and some preliminary results. 
 
Most of the sera were positive for AChR antibodies by RIPA and by CBA in the serum 
and there was a wide range of antibody levels in the cohort, as expected. Clustered 
AChR antibodies were also detected on CBAs as is typical (Leite et.al., 2008, 
Rodriguez-Cruz et.al., 2015) and it was disappointing that the same did not apply to the 
thymic cultures; there is previous evidence from competition studies with monoclonal 
antibodies to human AChR, that the characteristics of thymic and serum antibodies are 
similar (Heidenreich et.al., 1998). Higher levels of the antibodies in the thymic cultures 
would have provided more robust results. 
 
After screening sera and supernatants of the MG patients, this study further proceeded to 
develop a method of obtaining membrane vesicles from the transfected cells. The idea 
was to use membrane vesicles as a source of antigen for identifying the specific B cells 
and also potentially as a source for antigen presentation. Harvested AChR membrane 
vesicles after testing were presented with subsets of B cells to try to sort the antigen 
specific B cells from the pool of lymphocytes. It was first necessary to try different 
methods to obtain CD19 specific memory B cells and to sort the B cells and its subsets 
in PBMCs using 4 healthy individuals, one in each experiment, to optimize the method 
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and technique of presenting B cells to antigens. Unfortunately, it was not appropriate to 
make comparisons between them or with MG patients. 
 
In neuromyelitis optica (NMO), an autoantibody specific for aquaporin-4 (AQP-4), a 
water channel protein, was identified (Lennon et.al., 2005). There is accumulating 
evidence that NMO is pathologically different from MS and represents a distinct disease 
entity with antibody-mediated astrocytopathy. Transfer experiments have demonstrated 
that the Aqp-4 antibody can induce astrocyte pathology on transfer to the brain in 
animals after disruption of the blood–brain barrier or by intra-cerebral injection with 
complement (Saadounet.al., 2010). In addition, the AQP4 antibody titer seems to 
correlate with disease activity, further supporting the concept that AQP-4 is a major 
target of the autoimmune response in NMO. Although some cloning of B cells has 
already been performed by other groups (Wilson et.al., 2018), the identification of B 
cells specific for AQP4 antibodies would be a major advance.  
 
Currently one of the most popular treatments for B cell mediated diseases is therapeutic 
depletion of CD20-positive B cells. Anti-CD20 (rituximab, Rituxan®) was initially 
developed to treat non-Hodgkins B-cell lymphoma and has shown promising results in 
treatment of CNS demyelinating diseases. Although rituximab is not cell specific, since 
it kills all the B cell subsets, use of the drug in lymphoma led to trials of rituximab and 
subsequent anti-CD20 specific antibodies in MG and NMO. For example, in a small 
open-label pilot study evaluating B-cell depletion in neuromyelitis optica (NMO), seven 
out of eight patients receiving rituximab experienced substantial improvement of 
neurologic function (Jariuset.al., 2008). It appears that rituximab immediately abolishes 
cellular B-cell functions, such as B-cell antigen presentation, whereas antibody titres 
appear to decrease with a substantial delay because antibody-secreting plasma cells no 
 
tissues provide a majority of immunoglobulin sequences, but cannot be relied upon to 
longer express CD20. Based on this assumption, it seems that that the immediate benefit 
of B-cell depletion in T-cell-mediated autoimmune disease may relate to an impaired 
activation of T cells by the B cells rather than a direct effect on antibody production. 
 
Another disease that could be approached in a similar way is multiple sclerosis. 
Evidence for a role of antibodies in MS derives from histopathological studies in which 
B cells, as well as B-cell-derived plasma cells and antibodies, are found in the central 
nervous system (CNS). Antibodies are frequently observed in acute lesions of MS 
patients and in newly diagnosed patients, histopathological studies demonstrate 
heterogeneity of acute lesions between individual patients suggesting at least four 
distinct patterns of acute demyelinating lesions (Keegan et.al., 2005). The most frequent 
pattern is characterized by significant antibody deposits and complement activation 
suggesting B cell involvement. Of importance, molecular analyses of B cells in brain 
lesions demonstrate an accumulation of clonotypic B cells with preferential use of 
particular variable (V) heavy (H) chain (VH) genes suggesting a restricted local immune 
response. Furthermore, investigated sequences showed signs of hypermutations 
reflecting an ongoing and maturating B-cell response to the target antigen (Colombo 
et.al., 2000). However, other studies suggest that the immunoglobulin G heavy chain 
repertoire in multiple sclerosis plaques is not entirely distinct from the heavy chain 
repertoire in peripheral blood lymphocytes (Bankoti et.al., 2014) making the peripheral 
nervous system worth studying further. 
 
If the B cells could have been identified more convincingly in this study, the next step 
would be fractionation of the cells and amplification of immunoglobulins to create 





provide correct pairings of heavy (VH) and light (VL) chain V regions. A single cell- 
based methodology is necessary to yield correctly paired VH + VL Fab. A simple 
method for the amplification of correctly paired IgG κ or λ Fab from single human B 
cells or plasma cells that combines the best features of related methods, and improves 
them by optimization and simplification. This method has the advantage of versatility, 
sensitivity and reliability, allowing amplification of correctly paired Fab from different 
cell types and sources. The method almost invariably provides pure mRNA extracts and 
has built-in controls for the detection of template contamination. Sequence analysis of 
immunoglobulin (Ig) heavy and light chain transcripts can refine categorization of B cell 
subpopulations and defines the selective forces that act during immune responses or 
immune dysregulation, such as autoimmunity, allergy, and B cell malignancy 
(Rogosch et.al., 2012). 
 
 
A novel and user-friendly tool was described for easier analysis of cloned IgG sequence 
for the extensive analysis and graphical presentation of a very large collections of Ig 
transcripts which have been pre-analyzed by IMGT/HighV-QUEST. (Rogosch et.al.,2012) .  
 
Ig AT additionally calculates the probability of antigen-driven selection within Ig 
repertoires and predicts structural properties of the antigen-binding site. IgAT can be 
used to analyze up to 150 kDa human or murine heavy or light chain transcripts in a 
single run of the application and automatically generates 25 Microsoft® PowerPoint® 
graphics files illustrating key characteristics of the Ig repertoire, such as VDJ gene 
utilization, amino acid use. IgAT readily yields the necessary data to allow statistical 
and graphical comparisons between various repertoires. (Rogosch et.al., 2012). 
However, this technique was not used in this project. 
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In autoimmune diseases in which pathogenic or excess IgG antibodies are the etiological 
agents, such as myasthenia gravis, bullous pemphigoid, idiopathic thrombocytopenic 
purpura (ITP), and systemic lupus erythematosus (SLE), it is sometimes advantageous  
to reduce endogenous serum IgG levels by interfering with FcRn function. One possible 
way to interfere with the function of FcRn is to overload it with “innocuous” IgG. As 
FcRn functions as the IgG homeostatic receptor, the level of FcRn expression 
determines the serum concentration of IgG. Administering large quantities of exogenous 
IgG raises the serum concentration above this equilibrium set point and saturates FcRn 
(Yu & Lennon, 1999). As a result, the excess IgG that does not bind to FcRn enters the 
degradative pathway. This results in a shortening of the serum IgG half-life. High-dose 
IVIG treatment is thought to exert an immunomodulatory effect by numerous 
mechanisms, including engagement of the inhibitory FcγRIIb receptor (Samuelsson 
et.al., 2001) and by FcRn saturation. 
 
Advances in our understanding of the pathophysiology of MG have led to more effective 
treatments for this condition and have implications for other antibody-mediated 
disorders. Earlier disease recognition combined with prompt appropriate treatment are 
key factors in improving the prognosis of MG. Therefore, the need to educate and 
improve disease awareness is important in the diagnosis and management of this 
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